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1.STRESS 
Stress is a common experience of daily life and all organisms have developed 
mechanisms to cope with it. Sustained stress can have numerous pathophysiological 
effects such as activation of neuro-endocrine [limbic-hypothalamic-pituitary 
adrenal system] (Bonfiglio et al., 2011) and hormonal (corticosterone release) 
functions (Fuchs & Flugge, 1998). Sustained and persistent stressful conditions can 
precipitate anxiety and affective disorders such as depression, which further leads to 
the excessive production of free radicals and oxidative burden (Maes et al., 2011).  
Stressful events can activate the Hypothalamo-Pituitary-Adrenal (HPA) axis 
(Kvetnansky et al., 2002) and increase the release of Corticotrophin Releasing 
Hormone (CRH) from the hypothalamic paraventricular nucleus, causing the 
secretion of Adrenocorticotropin (ACTH) from anterior pituitary, which in turn 
stimulates the secretion of glucocorticoids from the adrenal cortex (Pacak et al., 
1993; Venihaki et al., 1997). Glucocorticoids possess broad spectrum of actions 
affecting expression and regulation of genes throughout the body readying the 
organism for changes in energy and metabolism required for coping (Akil & 
Morano, 1995; Levine, 2005). Stress has been postulated to be involved in the 
etiopathogenesis of a variety of disease state including hypertension, coronary heart 
disease (Roy et al., 2001), gastric ulcers (Yadin & Thomas, 1996), diabetes 
(Fitzpatrick et al., 1992), immuno-suppression (Purret, 2001), mental depression, 
memory loss (Gareri et al., 2000), and host of other diseases. The resultant 
disturbances may vary depending upon type, intensity, and the duration of a 
particular stressor and the strain\sex differentiation of the subjects (Kioukia-Fougia 
et al., 2002). Different animal models for stress have been developed and used 
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frequently to evaluate the anti-stress activity of compounds of both natural and 
synthetic origin.  
In an organism, diverse stressors activate a wide spectrum of interacting hormonal 
and neuronal systems resulting in behavioral (anxiety disorders, decrease in food 
intake, decrease in sexual behavior, and loss of cognitive function) and physiological 
responses [activation of pituitary adrenal axis and release of glucocorticoids into the 
blood stream] (Henry & Stephens, 1977). These stressors are stimulators of arousal 
and lead to autonomic (changes in body temperature and tachycardia) and behavioral 
changes; however, when arousal increases to stress‐like levels, it results in 
psychiatric and physical disorders (Hennessy et al., 1979) [Figure 1]. Different 
animal models have been developed for chronic stress  induced neurological 
disorders such as the olfactory bulbectomy model, and the chronic unpredictable 
stress model. These animal models are used to screen various new chemical entities 
and to develop a better understanding of the underlying molecular pathway in 
chronic stress pathology. Stress responses are variable and there are individual 
differences both physiologically and behaviorally in how an organism perceives a 
perturbation and in the resulting adaptational/maladaptational processes (Weiner, 
1992). 
Stress and Stressors 
Stress can be defined generally as responses to demands upon the body (Koob, 
1999). It is the body’s reaction to a change that requires a physical, mental, or 
emotional adjustment or response (Selye, 1936). It can come from any situation or 
thought that makes one feel frustrated, angry, nervous, or anxious. Conceptually, 
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stress can be any threat, either real or perceived, to the well being of an organism 
and it can be of two types. 
Kumar, et al.: Stress 
Figure 1: Relationship between arousal, psychological stress, physical stress and 
pathology 
 
Stressor is a stimulus, either internal or external, that activates the hypothalamic 
pituitary adrenal (HPA) axis and the sympathetic nervous system resulting in 
physiological change (Maier & Watkins, 1998). Long‐term exposure to stressors can 
cause depression, (Nirmal et al., 2008) post‐traumatic stress disorder, and anxiety 
disorders. The degree of behavioral control that an individual has over a stressor 
often determines the consequence of that stressor and plays a key role in the 
development of pathological behaviors after a traumatic event (Christianson et al., 
2009). The potency to cope with the stressors is a fundamental requirement for 
survival. Brain is the target for different stressors because of its high sensitivity to 
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stress‐induced degenerative conditions (Sahin & Gumuşlu, 2007). The brain tissue is 
made up of large amounts of polyunsaturated fatty acid, thus making it vulnerable to 
free radical attacks (Gutteridge, 1995). 
Consequences of Stress 
Normal development and preservation of life and species depend on a normally 
functioning stress system. Maladaptive neuroendocrine responses, i.e., dysregulation 
of the stress system, may lead to disturbances in growth and development, and cause 
psychiatric, endocrine/metabolic, and/or autoimmune diseases or vulnerability to 
such diseases. 
Stress and anxiety 
According to previous reports stress induces anxiety‐like behavior in both humans 
and animals (Liezmann et al., 2011). In response to stress, there is an increase in 
CRF levels. The CRF level decreases when the stressor is no longer present. Lee, et 
al. reported that chronic stress increases the length and volume of expression of CRF 
in areas of the brain associated with fear and emotion, including the amygdale (Lee 
et al., 2008) [Figure 2]. Such chronic stress changes the body’s response, and the 
resulting increased expression of CRF is believed to be the cause of health‐related 
stress problems such as anxiety, depression, and infertility (Kimura et al., 2010). 
Exposure to stress represents an important factor for a number of neuropsychiatric 
disorders such as depression, post‐traumatic stress disorder, and other anxiety 
disorders (Horstmann& Binder, 2011). There are earlier reports of enhanced 
noradrenergic or HPA axis activity in many psychopathological states such as 
depression and anxiety disorders (Boyer, 2000; Kendler, 1996).  
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Figure 2: De novo synthesis pathway of melatonin. 
Oxidative stress contributes toward neuronal degeneration in the central nervous 
system in the process of aging as well as neurodegenerative diseases (Hovatta et al., 
2010). The production of reactive oxygen species (ROS) is greatly increased under 
many conditions of toxic stress (Liu & Schubert, 2009). One of the reasons for 
stress‐induced enhancement of free radicals may be the elevation of nitric oxide 
(NO) production (Matsumoto, 1999). This is further supported by the present 
determination of nitrite levels, which revealed significant increase in brain NO 
levels in stressed mice. The reactive nitrogen species along with ROS, working in 
concert with an inflammatory process, may play a substantial role in the 
pathogenesis of depression (Matsumoto, 1999). Stress has been shown to be 
responsible for the depletion of several free radical detoxifying enzymes such as 
glutathione peroxidase, catalase, and superoxide dismutase (Zaidi & Banu, 2004). 
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This results in oxidative burden, which has been implicated in stress as well as in the 
pathogenesis of several disease states. Since brain tissues consist of a high content of 
polyunsaturated fatty acids and one of the important consequences of oxidative 
stress is peroxidation of membrane lipids, this reaction produces marked damage to 
the structure and function of cell membranes in these tissues (Jain et al., 1991). 
Therefore, lipid peroxidation was supposed as the major biochemical alteration and 
consequence of oxidant‐induced cell injury. Thus, the important consequences of 
stress could be attributed to stress‐induced lipid peroxidation. 
Stress and immunological changes 
Stress has been associated with impaired immune function and increased 
susceptibility to infectious diseases (Connor & Leonard, 1998). It is now believed 
that the nervous, endocrine, and immune systems are so intimately connected that 
they should be regarded as a single network rather than as three separate systems 
(Connor & Leonard, 1998). It is widely accepted that psychological stress and 
psychiatric illness can compromise immune function (Leonard, 1995) and soluble 
mediators released by immune cells can affect the central nervous system, thus 
producing alterations in behavior. Exposure to stressful life events such as academic 
examinations and divorce was reported to cause impairments in various aspects of 
cellular immune function (Bartrop et al., 1977). There are also reports of immune 
activation, (Bartrop et al., 1977) in addition to immunosuppression in both the 
depressed and subjects exposed to stressful life events. 
 A requirement of all studies on stress is an adequate and appropriate animal model 
of stress. An ideal animal model should be able to reproduce each of the aspects of 
stress response and should be able to mimic the natural progression of the disease. 
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However, none of the models available is able to entirely reproduce stress response. 
Some models reproduce physical stress and associated neuroendocrine changes 
(Kvetnansky & Mikulai, 1970), whereas others better reproduce the psychological 
stress and associated behavioral changes (Marcelo et al., 2007). Acute models do 
not reproduce the neuroendocrine dysfunction whereas a chronic model might be 
able to do so. Therefore, a correct model should be used to evaluate specific aspects 
of the stress response. Each model has inherent limitations including lack of 
stability, lack of predictability of tissue damage, and lack of adjustability. And hence 
a literature survey of more than 35 years (1970-2007) was conducted based on the 
description of the models, potential utilization of the models, and value of the 
models for testing of new medical interventions for the management of stress. The 
purpose of this review was to assess different models of stress. 
 
 
 
   
 
 
       
  
Different Types of Stress (Based on the 
Time Period of Application of Stressor) 
Acute 
Stress 
(Single Application of 
Stressor) 
Chronic 
Stress 
(Application of Stressor for 
a Long Period of Time) 
Chronic Variable Stress 
(Repeated Application of 
different types of stressors 
of Variable Intensity) 
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ANIMAL MODELS COMMONLY USED  
• Physical stress models  
Animal models of stress that use physical stress can be subdivided into: 
¾ Temperature fluctuation induced stress:  
1. Immersion in cold water with no escape  
2. Cold environment isolation  
o Immobilization induced stress  
o Electric foot shock induced stress  
o Forced swimming induced stress  
• Psychological stress models  
Animal models of stress that use psychological stress can be subdivided into:  
¾ Neonatal isolation induced stress  
¾ Predatory stress  
¾ Day-night light change induced stress  
¾ Noise induced stress.  
• Chronic unpredictable stress 
Different stressors of mild to moderate intensity are applied on variable basis so as 
to prevent the emergence of adaptation or resistance to one particular type of 
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stressor. It involves the use of both physical and psychological stress models in a 
random way. 
PHYSICAL STRESS MODELS  
Temperature fluctuation induced stress  
Acute change in temperature leads to stressful conditions by activation of 
temperature regulatory centre in the hypothalamus and subsequently HPA axis. It 
leads to acute release of adrenocortical hormones in the blood stream responsible for 
acute stressful response (Sapolsky et al., 1986). A sharp decrease in temperature 
using either cold water or freezer has been used frequently to induce acute stress.  
1. Immersion in Cold Water (ICW)  
In this method, the rats are placed individually in a tank of cold water (depth = 15.5 
cm; temperature = 15-20°C) where they either swim or remain in an upright 
position, keeping their heads above water level (Retana-Marquez et al., 2003; Iwona 
et al., 2003; Fernandez-Landiera, 2004; Yun et al., 2003). This situation lasts for 15 
minutes unless the rats sink. In that event, rats are removed before the cutoff time 
and are not included in the experiments. For acute stress, rats are sacrificed 30 
minutes after the stress exposure. For chronic stress, animals are exposed to this 
stressor for 7-10 days. Rats are sacrificed 1 h after the last stress session. The major 
advantage of this type of stressor is that acute stress can be achieved in a relatively 
short period of time. However the major drawback of this model is that the body 
adapts to change in temperature on chronic exposure to low temperature and hence 
stress response gets highly diminished (Pitman et al., 1988; Blustein et al., 1998).  
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2. Cold environment isolation  
In this method, rats are individually kept in a freezer with a temperature maintained 
at 4°C. The rats are kept for 15 minutes once for acute stress and for 7-10 days to 
develop chronic stress (Kvetnansky et al., 1971). This sharp fall in temperature leads 
to a sharp increase in the level of adrenocorticoids as explained above culminating in 
the development of stress response (Kvetnansky et al., 2002; Staratakis & Chrousos, 
1995). Unlike the ICW model, rats are prevented from drowning in cold water hence 
it is relatively safe model however it also suffers from same drawback of 
development of resistance/adaptation on chronic exposure.  
Immobilization induced stress  
Immobilization has been used extensively as a stressor for the study of stress-related 
biological, biochemical and physiological responses in animals (Kvetnansky & 
Mikulai, 1970; Kasuga et al., 1999; Marty et al., 1997). Immobilization can be 
produced in two different ways. Animal can be either kept immobilized in a semi 
cylindrical acrylic tube (4.5 cm diameter and 12 cm long) with proper holes in it for 
air to pass (Das et al., 2000). Another way is to keep the animal with its limbs 
stretched on a board and its limbs are immobilized with adhesive tape. Movement of 
head is restricted by keeping the head in a metal loop coiled around the neck. The 
rats are kept immobilized in either of the above two ways for 150 minutes once to 
produce acute stress and for 7-10 days to produce chronic stress (Dronjak & 
Gavrilovic, 2006). The major advantage of using immobilization as a model of stress 
is that it produces an inescapable physical and mental stress to which adaptation is 
seldom exhibited (Kasuga et al., 1999).  
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Electric foot shock induced stress:  
Electric foot shock (EFS) of mild intensity has also been used as a stressor. Rodents 
are very susceptible even to mild shock and exhibit rapid stress response. 
Researchers have used electric foot shock of varying degree to produce stressful 
conditions and hence to evaluate adaptogenic activity of various compounds. Stress 
by electric foot shock is given by placing the rats individually in a chamber with an 
electrified floor. Rats receive unavoidable electric foot shocks with an intensity of 3 
mA, 200 ms of duration and a frequency of 1 per second over a 5-min period. For 
acute stress response, the rats are exposed once and sacrificed after 15 minutes of 
stress. Chronic stress is also produced by repeating the same treatment for 7-10 days 
and rats are sacrificed 1 h after the last stress session (Retana-Marquez et al., 2003). 
Some researchers have modified the method in which rats are subjected to 
inescapable electric foot shock for 60 minutes (0.15 mA shock, on a variable interval 
schedule with a mean inter shock interval of 60 seconds) (Taysse et al., 2005). The 
biggest advantage of this model is that it effectively produces high degree of stress 
in the animal. The major disadvantage of this model is the hazard of electric shock 
causing death of the animal and special caution that is required to perform this 
methodology. 
Forced swimming induced stress  
It is the tendency of the living being to escape or avoid a noxious stimuli/condition. 
If the animal is not able to escape the stressful stimuli or it feels threatened, the 
animal will show stress response. This principle is used for developing forced 
swimming model for inducing stress in laboratory animals. In order to produce 
swimming induced stress, rats are made to swim in a cylinder (30 cm diameter and 
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filled to a height of 20 cm with 15 cm of space above the head of the rat) for a single 
session of 2 h duration for acute stress, or for one 2 h session a day for five 
consecutive days for chronic stress (Ferry et al., 1991). Some authors have used 
forced swimming in warm (20°C) water for 3 minutes with the total session lasting 
for 1 h (Kitchen & Pinker, 1990). Although forced swimming induced stress is a 
highly safe model, adaptation to chronic swimming induced stress has been reported 
and inter-strain differences between rats to forced swimming behavior have also 
been documented (Armario et al., 1995). 
PSYCOLOGICAL STRESS MODELS  
Neonatal isolation stress  
Early life events have profound consequences on subsequent quality of life. It has 
been shown that the early life stress of neonatal isolation in rats has immediate and 
enduring neural and behavioral effects (Kuhn et al., 1990). Such effects may reflect, 
in part, stress-induced morphological changes in hippocampus and other brain 
regions (Kosten et al., 2005b). In fact, the hippocampus provides negative feedback 
regulation of the hypothalamic-pituitary-adrenal (HPA) axis (Herman & Cullinan, 
1997) and hence neonatal isolation induced stress can represent the stress response 
that may lead to neuro-degeneration at an early stage of life. This stress procedure is 
also useful in evaluating the effect of stress on cognition and memory development. 
In the neonatal isolation procedure, the litter of the inbred strain is removed from the 
cage on second day after the birth, weighed and placed individually in an opaque 
plastic container (9 cm diameter and 8 cm deep) with no bedding for 1 h (between 
09:00 and 12:00) in a heated (30°C), humidity controlled chamber with white noise 
to mask other pups calls. The chamber has to be located in a room separate from 
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animal colony facility. Containers are placed 20-30 cm apart. After 1 h period the 
litters are placed back with their dams in home cage (Kosten et al., 2000; Kosten et 
al., 2004). This isolation procedure continues up to 8 days and hence it is used to 
induce chronic stress only. Neonatal isolation stress model has be used extensively 
to demonstrate the effect of early lifetime stress on vulnerability to addiction 
(Kosten et al., 2005a), and response to psychostimulants by impairment of 
hippocampal-dependent context induced fear in adult male rats.  
Predatory stress  
Direct encounter of an animal with its natural predator is one of the most stressful 
and anxiogenic event it can face and it leads to rapid development of „flight or 
fight response (Lupien et al., 2006). Exposure of rodents to natural predators or to 
their odors may induce stress like states (Adamec & Shallow, 1993). Under such 
circumstances, there is rapid sympathetic activation leading to rise in the levels of 
adrenocorticoids in blood causing acute stress response to develop. Direct encounter 
with a predator has been effectively used to evaluate the biochemical and 
physiological changes produced during such stressful conditions (Marilia et al., 
2007). Predatory stress in mice is induced by series of short exposures to natural 
predator like cat (Blanchard & Blanchard, 1989) or to any substance having the 
odor of cat like the fecal pellets of cat (Berton et al., 1998). In one of the methods, 
mice are placed individually in different cages and after four initial 20-min cage 
habituation sessions each subject is submitted to two randomly-assigned 20-min 
predator confrontation sessions. Change in behavioral pattern such as locomotion, 
shrieking like voices and endocrinological changes after the stress exposure are 
observed (Blanchard et al., 1998). Another free-exploration test (Griebel et al., 
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1993) was used consists of a PVC box (30x20x20 cm) covered with Plexiglas and 
subdivided into six equal square exploratory units, which are all interconnected by 
small entries. It could be divided in half lengthwise by closing three temporary 
partitions. Approximately 20 h before cat exposure, each subject is placed in one 
half of the apparatus with the temporary partitions in place, in order to be 
familiarized with it. The floor of this half was covered with fresh sawdust and the 
animal is given unlimited access to food and water. On the test day, mice of each 
strain are randomly allocated to the following four groups.  
(a) Naive clay: animals are exposed to both familiar and novel compartments by 
removal of the temporary partitions. The novel compartment contains three 
modeling odor-free clay pellets.  
(b) Naive feces: animals are exposed to both familiar and novel compartments. The 
novel compartment contains three cat feces pellets.  
(c) Exposed clay: subjects are removed from the free-exploration box and 
confronted individually with a cat during a 5 min. session. The cat cage consists of a 
PVC box (82x56x62 cm) subdivided into two compartments, one containing the cat, 
the other the mouse. Separation consists of a transparent PVC wall with holes 
allowing the cat to reach the other side with its paws. The mouse is then put back in 
the free-exploration apparatus and is exposed 1 h later to both familiar and novel 
compartments. The novel compartment contains three modeling odor-free clay 
pellets.  
(d) Exposed feces: same as previous group, but the novel compartment contains 
three pellets of feces from the cat used during exposure. The behavior of the mouse 
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is observed under red light for 5 min via a closed circuit TV camera by an observer 
located in an adjacent room.  
The following parameters are recorded:  
(a) Time spent in the novel compartment; (b) total unit entries and (c) total number 
of rearings.  
The results are expressed as mean percentage of time spent in the novel 
compartment, mean total number of novel unit changes, and mean total number of 
rearings. Marmosets (Callithrixpenicillata) have also been employed for induction 
of predatory stress in a test battery known as Marmoset Predator Confrontation Test 
[MPCT] (Cilia & Piper, 1997). This model compares the behavioral response of 
experienced versus naïve adult black tufted-ear marmosets in confrontation with a 
taxidermized wild-cat predator stimulus. After four initial 20-min cage habituation 
sessions, each subject is submitted to two randomly-assigned 20-min predator 
confrontation sessions. Confrontation with the predator induces significant 
behavioral changes; i.e., proximic avoidance and tsik-tsik alarm call. Anti-stress 
drug administration, concomitant to predator exposure, reverses the behavioral 
changes observed (Barros et al., 2004). Predator induced stress is an established 
model to induce short term acute stress response but its major disadvantage is 
development of habituation to predator exposure hence the use of this model for 
inducing stress is justified for developing only acute stress.  
Day-night light change induced stress  
Changes in the circadian rhythm have profound effect on physical and psychological 
well being of an individual (Atcheson & Tyler, 1975). Laboratory animals, when 
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subjected to abrupt changes in day-night light pattern, exhibit acute stress response 
(Kosten et al., 2005b). Changes in circadian rhythms are regulated by pineal gland 
through the secretion of melatonin (Nicholsonet al., 1985). Melatonin is released 
from the pineal gland in response to dark or dim light where as its functional 
antagonist serotonin is secreted in response to bright light. It is this serotonin-
melatonin cycle that is responsible for regulation of sleep-awake state of the body 
(Bermudez et al., 1983; Hamm et al., 1983). To induce stress, cages of rat or mice 
are kept under bright light from 19:00 h over night (in the dark phase) and cages are 
kept in dark room with no light from 12:00 h in the light phase for 180 minutes for 
7-10 days (Marcelo et al., 2007). This method is suitable for inducing short term 
stress response. Generation of stress can be evaluated by measuring the biochemical 
parameters associated with chronic stress response (Rai et al., 2003). The major 
disadvantage of this model is that it can be effectively used to generate short term 
stress response as on repeated exposure to this type of stressor, the animal adapts to 
the changed day-night light pattern. This major drawback can be minimized by using 
this model as a part of chronic unpredictable stress protocol. 
Noise induced stress  
Noise as a stressful stimulus is a widely accepted fact. A large number of people are 
exposed to potentially hazardous levels of noise levels in daily modern life. 
Experimental studies have demonstrated ultra structural modifications in rat 
cardiomyocytes mainly in mitochondria due to noise stress. These subcellular 
alterations are related to an imbalance in calcium homeostasis, which is supposed to 
be sustained by increased catecholamine innervations (Paparelli et al., 1992). When 
noise exposure of any kind exceeds 90 dB, noise becomes a stressor (Ramsey, 1982). 
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Noise stress has a depletory effect on free radical scavenging enzymes in the brain 
leading to moderate to severe oxidative stress (Samson et al., 2005) which can be a 
potential basis for hearing loss (Fechter, 2005). Noise stress in laboratory rats can be 
produced by loudspeakers (15 W), driven by a white noise generator (0-26 kHz), 
installed 30 cm above the cage. Thus a noise level can be set at 100 dB or above 
uniformly throughout the cage and can be monitored by a sound level meter. Each 
animal to be treated is exposed to noise stress for 4 h/day for 15 days. Control group 
rats are also kept in the above described cage during the corresponding period of 
time, without noise stimulation to avoid the influence of handling stress on 
evaluation of effects due to noise exposure (Ravindran et al., 2005; Manikandan & 
Devi, 2005). The effect of noise stress exposure can be determined by estimating the 
brain biogenic amine level.  
CHRONIC VARIABLE (UNPREDICTABLE) STRESS MODELS  
The major disadvantage of both physical stress models and psychological stress 
models is the development of adaptation / resistance on chronic exposure. The 
changes in physiological and behavioral responses to chronic stress can be related to 
the adaptation of the HPA axis. When the same stressor is repeated, the HPA 
response undergoes desensitization or become stable as it has been reported that 
rodents repeatedly exposed to restraint stress exhibited a habituated corticosterone 
response, when they were subsequently challenged with an acute exposure to 
restraint (Magarinos & Evans, 1995; Gadek-Michalska & Bugajski, 2003). On the 
other hand, the exposure to a multiple stress paradigm produced continued elevation 
in corticosterone levels, when the animals were subsequently subjected to acute 
restraint stress (Magarinos & Evans, 1995). It has also been suggested that the 
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adaptations of HPA axis depend on type, duration and severity of the stress regime 
(Blanchard et al., 1998; Gadek-Michalska & Bugajski, 2003). To prevent the 
development of resistance, Chronic Unpredictable Stress (CUS) models have been 
developed which involve the use of various physical and psychological stressors in a 
predetermined manner so that the animal is not able to adapt to the stressor. 
Adaptation to one type of stressor has been effectively prevented by employing 
various stressors such as immobilization stressor for 15 minutes followed by 
overnight sleep deprivation and rotation of the cage at a predetermined speed 
(horizontal shakes at high speed) for 50 minutes followed by swim stress in water 
(20ºC) of 4 minutes (Ortiz et al., 1996). Wetting the saw dust bedding of the animal 
all day to restrict movement followed by electric foot shock (ten shocks of one 
second duration each, in an unpredictable manner, at the intensity level of 0.4-1.8 
mA) and stroboscopic light (for 13 h, 10 Hz) has also been used as a part of CUS 
protocol (Margus et al., 2007). Some researchers have used exposure to predator 
odor induced stress as a part of CUS protocol, in which mice are placed in a novel 
cage containing cat litter soiled with cat feces and urine (Anisman et al., 2007). 
Various authors have modified the stress models in order to accommodate them in 
their respective CUS protocol. Other additional stressors that have been applied as a 
part of CUS protocol are tail pinch with a clothes-pin placed 1 cm distal from the 
base of the tail for 5 min, strong illumination during predicted dark phase for 12 h, 
movement restriction in a small cage (11 cm x16 cm x 7 cm) for 2 h (Ortiz et al., 
1996), ether anaesthesia until loss of reflex (Renard et al., 2005), and subcutaneous 
0.9% saline injection (Ladd et al., 2004). Chronic variable stress models have been 
proven to be more useful as they are devoid of the problem of resistance in the 
animal species towards the commonly used stressors and also have the advantage of 
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the development of effective and long-term stress response. Thus CUS models are 
nowadays the preferred models for generation of a stress response. 
Stress has been postulated to be involved in the etiopathogenesis of a variety of 
disease state including hypertension, coronary heart disease (Roy et al., 2001), 
gastric ulcers (Yadin & Thomas, 1996), diabetes (Fitzpatrick et al., 1992), 
immunosuppression (Purret, 2001), mental depression, memory loss (Gareri et al., 
2000), and host of other diseases. 
NEURODEGENERATIVE DISEASE 
Neurodegenerative diseases comprise a wide range of diseases that share the 
common characteristic of progressive loss of structure or function of neurons and 
glial cells in the brain and spinal cord. Many neurodegenerative diseases are a result 
of neuronal loss, although glial cells are also involved (Glass et al., 2010). 
Neurodegenerative diseases present a chronic and slowly progressive process. 
Neurons in neurodegenerative diseases are affected by neuronal dysfunction at the 
level of synaptic transmission, synaptic contacts, and axonal and dendritic 
degeneration. In different neurodegenerative diseases, neurite degeneration and cell 
loss of neurons are present within specific neurotransmitter populations. In addition, 
numbers of functional neurons in neurogenic regions, and adult neurogenesis are 
altered or decreased. Adult neurogenesis increases after several acute pathologic 
stimuli, including stroke, seizure and acute trauma (Arvidsson et al., 2002; Rice et 
al., 2003; Parent, 2007). Brain regions differ in their vulnerability to aging; some 
regions that are very sensitive to age-related neurodegenerative changes are the 
dentate gyrus (DG) of the hippocampus, subiculum (Small, 2003) and subventricular 
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zone (SVZ) ⁄ olfactory bulb (OB) (Braak et al., 2003). The generation and cell death 
of newly generated cells have critical roles in brain development and maintenance in 
the embryonic and adult brain, and alterations in these processes are seen in 
neurodegenerative diseases. 
DIFFERENT NEURODEGENERATIVE DISORDERS: 
Although neuronal degeneration predominantly affects or starts with specific 
neuronal populations [including DAergic neurons in PD, striatal medium spiny 
neurons in HD, motor neurons in amyotrophic lateral sclerosis, and cortical and 
hippocampal neurons in Alzheimer’s disease (AD)], there are many similarities 
between different neurodegenerative disorders. These include atypical protein 
assemblies and oligomerization as well as induced cell death. At a late disease stage, 
protein aggregation is no longer restricted to specific brain regions.  
Interestingly, in Parkinson’s disease (PD) and Huntington’s disease (HD), the 
specific alterations in neurogenic areas such as the DG and SVZ ⁄ OB system 
parallel the early or premotor symptoms that are seen in the early stages of 
neurodegenerative disease, such as depression, anxiety or olfactory dysfunction 
(Simuni & Sethi, 2008). Therefore, it is intriguing that the mechanisms of 
neurodegenerative diseases are closely linked to brain plasticity. Brain plasticity in 
the adult, originally conceived of as changes at the level of synaptic transmission, 
synaptic contacts and gene expression (reviewed in Buonomano & Merzenich, 
1998), became a more complicated concept. 
Genes that are key players in neurodegenerative diseases [α-synuclein, 
presenilin(PSEN)1, tau, huntington] are also physiologically involved in modulating 
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brain plasticity in the embryonic brain, specifically as membrane proteins and when 
concentrated in synapses. These proteins commonly show high conservation 
between species and are located close to membranes or are involved in microtubule 
transport. α-synuclein is a protein that is physiologically enriched in presynaptic 
termini (Abeliovich et al., 2000). Initially shown to be upregulated in a discrete 
population of presynaptic terminals of the song bird brain during a period of 
acquisition-related synaptic rearrangement (George et al., 1995), α-synuclein can 
interact with tubulin (Alim et al., 2002). In addition, it is involved in dopamine (DA) 
synthesis, metabolism and release, and slight changes in concentration can have vast 
effects on neurotransmitter release (Nemani et al., 2010). 
NEURODEGENERATION IN DIFFERENT DISORDERS: 
In non-pathological aging, cognitive impairment would seem easiest to attribute to 
the effects of oxidative stress, inflammatory reactions and changes in the cerebral 
microvasculature (Riddle et al., 2003). However, the aging brain in the absence of 
dementia is also affected to varying degrees by the neuropathological features. Many 
neurodegenerative diseases occur as a result of neurodegenerative processes 
including 
• Parkinson’s disease (PD)  
• Alzheimer’s disease (AD) 
• Huntington’s disease (HD) 
• Amyotrophic lateral sclerosis (ALS) and 
• Multiple sclerosis (MS) 
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Alzheimer's disease (AD) 
Alzheimer’s disease (AD) was first described by Alois Alzheimer more than a 
century ago in Germany, and it constitutes one of the most common causes of senile 
dementia.AD refers to a clinical syndrome that occurs in the elderly and is severe 
enough to interfere with social and occupational activities. At least two clinical 
abnormalities are essential for diagnosis of the disease, namely, memory loss in an 
alert person and impairment of one or more of the following functions: language, 
attention, perception, judgment or problem solving (Forstl & Kurz, 1999). 
The pathology of AD includes neuronal and synaptic loss, neurofibrillary tangles 
due to hyperphosphorylated tau proteins and deposition of amyloid-β (Ab) protein in 
senile plaques in the basal forebrain cholinergic neurons as well as in the cortex, 
hippocampus and amygdala (Hardy & Selkoe, 2002). Ab is the product of 
proteolysis of amyloid precursor protein (APP) by b- and c-secretase enzymess.  
 
Fig.3 Changes in Tau protein lead to microtubule disintegration 
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Fig.4 "Tangles" of a protein called "tau" occur in Alzheimer's patients'  
brains-causing neurons to lose their function and increasing memory loss. 
Illustration: National Institute on Aging/U.S. National Institutes of Health. 
 
[β amyloid]         [Normal Neuron]         [Amyloid Plague] 
Fig.5 Enzymes act on the APP (amyloid precursor protein) and cut it into fragments. 
The beta-amyloid fragment is crucial in the formation of senile plaques in AD. 
Ab accumulates intracellularly in the neuronal endoplasmic reticulum but also 
extracellularly (Trojanowski & Lee, 2000; Cuello, 2005). Although Ab plaques are 
the neuropathological hallmarks of AD, the small Aboligomeric species rather than 
its amyloid counterpart is thought to be the toxic culprit in the disease. Evidence for 
this assumption includes a correlation between oligomerization and memory deficit 
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in both transgenic mice and humans, the presence of oligomers in the brains of 
transgenic mice, the toxicity of Ab dimer and trimer measured by long-term 
potentiation, and lack of a good correlation between plaque amount and AD (at least 
in the early phase of the disease) (Walsh et al., 2002; Walsh & Selkoe, 2007). Patient 
deficits include olfactory deficits, memory impairment, cognitive and functional 
decline, and death. These symptoms can be partly related to regions and functions of 
adult neurogenesis.  
Parkinson’s disease (PD) 
Parkinson disease (PD) is the second most common neurodegenerative disease, 
affecting about 1% of the population over 65 years of age. PD is characterized 
clinically by resting tremor, rigidity and bradykinesia, resulting from the progressive 
and selective loss of dopamine (DA) neurons in the substantianigra (SN) pars 
compacta, and histopathologically by the eosinophilic proteinaceous 
intracytoplasmic inclusion known as Lewy bodies (LBs) in surviving dopaminergic 
cells (Forno, 1996). The etiopathogenesis of PD is probably multifactorial, 
including both environmental and genetic factors (Di Monte, 2003; Hardy et al., 
2003). Asmentioned above, α-synuclein (α-syn) is the principal component of LBs 
(Spillantini et al., 1997). This was seen in molecular genetic investigations that 
identified autosomal dominant missense mutations of α-syn (A53T) in heritable 
cases of PD (Polymeropoulos et al., 1997). Another missense mutation on the α-syn 
gene (A30P) was associated with familial PD (Kruger et al., 1998) and a new 
mutation (A46K) was found recently in a Spanish family, associated with PD, 
dementia of Lewy bodies (Zarranz et al., 2004).   
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It was suggested that α-syn aggregation is the key event that triggers neuronal 
damage and death (Forloni et al., 2000; Volles & Lansbury, 2003). In this context, 
α-syn mutations would speed up the protein aggregation (Conway et al., 2000). It is 
likely that the α-syn concentration is crucial to switch from a physiological to a 
pathological condition, and only when a threshold concentration is reached do the 
deleterious effects of aggregation become evident. Misregulation in the homeostasis 
of α-syn (caused by mitochondrial complex I inhibition, environmental toxins, 
oxidative stress or proteasome impairment) would be sufficient to trigger α-syn 
chemical modifications and aggregation in sporadic PD too (Sherer et al., 2003; 
Norris et al., 2003).  
Loss of Dopaminergic neurons in the substantianigra of the midbrain and loss of 
other neurotransmitter phenotype neurons in other brain regions are characteristic 
neuropathological hallmarks (reviewed in Goedert, 2001). Prominent clinical 
features of PD are motor symptoms (bradykinesia, tremor, rigidity and postural 
instability) and non-motorrelated PD symptoms (olfactory deficits, autonomic 
dysfunction, depression, cognitive deficits and sleep disorders). Non-DA brain 
regions that are affected in PD have recently attracted increasing interest because the 
onsets of the non-motor symptoms linked to these neuropathological alterations are 
observed early in the course of the disease. They include rapid eye movement 
(REM) sleep behavior disorder, subtle cognitive deficits, depression, olfactory 
dysfunction and constipation (for review see Tolosa&Poewe, 2009). As described 
above, a subset of these functions is connected to the stem and progenitor cell 
populations in the hippocampus and SVZ ⁄ OB system. Interestingly, several 
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monogenetic forms of PD show a decreased gray matter volume in the hippocampal 
region (Reetz et al., 2010). 
Chaperone-like activity of α-synuclein: 
Chaperones are proteins that prevent irreversible protein aggregation and facilitate 
the correct folding of non-native proteins through regulated binding and release in 
vivo (Slavotinek & Biesecker, 2003). α–Syn (α–Synuclein) has been suggested to 
function as a chaperone protein in vivo because, besides lipids (Eliezer et al., 2001; 
Li et al., 2001; Davidson et al., 1998), it appears capable of interacting with a 
variety of ligands and cellular proteins (Ostrerova et al., 1999; Xu et al., 2002), thus 
modifying their activities. It has recently been reported that the amino-terminal 
portion of α–syn shares 40% a homology with molecular chaperone 14-3-3 
(Ostrerova et al., 1999), suggesting that the two proteins could sub serve the same 
function. The molecular chaperone 14-3-3 is particularly abundant in brain, where it 
comprises ~1% of total soluble proteins (Boston et al., 1982). Chaperone 14-3-3 
accumulates in LBs, participates in neuronal development and cell growth control 
(Fu & Masters, 2000), and prevents apoptosis by antagonizing BAD, a proapoptotic 
member of the Bcl-2 family (Yuan & Yanker, 2000; Fig. 6). α-Syn binds to many of 
the same proteins as 14-3-3 (Ostrerova et al., 1999), including three proteins known 
to affect cell viability, protein kinase C (PKC), BAD, and extracellular regulated 
kinase (ERK). α-Syn interacts with 14-3-3 (Ostrerova et al., 1999), and the 
interaction between the two proteins produces a 54 to 83 kDa protein complex in PD 
brain (Xu et al., 2002). This complex is selectively increased in substantianigra but 
not in cerebellum or cortex. Thus α-syn may sequester 14-3-3, leading to a reduction 
in the amount of 14-3-3 protein available to inhibit apoptosis and rendering the cells 
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more susceptible to cellular stresses (Xu et al., 2002; see also Fig. 6). Both 14-3-3 
and α-syn bind to tyrosine hydroxylase (TH), the rate-limiting enzyme in 
catecholamine synthesis, with divergent consequences: activity is stimulated by 14-
3-3 but inhibited by α-syn (Jenco et al., 1998). The physical and functional 
homology between α-syn and 14-3-3 suggests that α-syn may normally act as a 
protein chaperone to help the cell deal with the effects of increased stress as part of 
an initial effort by the cell to protect itself against the accumulation of damaged 
proteins (Ostrerova et al., 1999). However, overexpression of wild-type α-syn is 
toxic to dividing cells and overexpression of its mutant forms A53T or A30P 
exhibits even greater toxicity (Ostrerova et al., 1999), which may be due to 
inhibition of PKC and interaction of α-syn with BAD, ERK, or other proteins 
involved in signal transduction (Ostrerova et al., 1999). 
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Figure 6. α-Syn aggregation and toxic effects in dopaminergic neurons. A 
hypothetical scheme depicts various pathways that, leading to aggregation of 
natively unfolded α-syn, oxidative stress, or mitochondrial impairment, cause cell 
death. For further details, refer to text. DA-dopamine; DOPA- 
dihydroxyphenylalanine; LBs-Lewy bodies; MAO-monoamine oxidase; ROS- 
reactive oxygen species; TH-tyrosine hydroxylase; THP-phosphorylated tyrosine 
hydroxylase; Tyr-tyrosine; UPS-ubiquitin proteasome system. 
Huntington’s disease (HD) 
Hungtington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
characterized by motor dysfunction, cognitive impairment and psychosis (Sharp et 
al., 1995). The disease is caused by an IT15 gene mutation on chromosome 4 (Sharp 
et al., 1995). This mutation produces a CAG / polyglutamate repeat expansion in the 
gene’s protein product, huntington (Sharp et al., 1995). The DNA sequence CAG 
encodes the protein glutamate, an amino acid known primarily for its roles in 
metabolism and as a neurotransmitter (Cotman & Monaghan 1986; Kandel, 2001). 
Normal huntington protein contains 9-35 CAG repeats; however, its mutant form 
may contain up to 250 of these repeats (Cattaneo et al., 2002). Both forms of the 
protein are known to undergo caspase cleavage to generate smaller, truncated 
fragments; however, the mutant protein’s fragments are distinct in their correlation 
with neurodegeneration (Wellington et al., 2002). Researchers are unsure why the 
mutant protein’s CAG repeats cause HD; however, two theories exist to explain 
disease onset. One theory, the loss of function hypothesis, suggests that the CAG 
expansion disables huntington from carrying out its normal function (Catteneo et al., 
2002). A second theory, the gain of function hypothesis, suggests that the IT15 
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mutation produces a toxic huntington protein with a distinct conformation that 
enables it to stick to both itself and normal huntington (Catteneo et al., 2002).  
 
Figure 7. This conformation allows mutant huntington fragments to clump in 
aggregates and simultaneously inhibit the normal protein’s proper function 
(Catteneo et al., 2002). Despite these opposing hypotheses regarding the exact role 
of CAG expansion, one idea is accepted across the board: mutant huntington forms 
inclusions in cell nuclei depending on the length of its CAG repeat, and longer 
repeats correlate with an increased presence of huntington inclusions (Senut et al., 
2000). Moreover, these nuclear inclusions are associated with premature neuronal 
cell death, especially in the striatum and globuspallidus (Hickey & Chesselet, 2003). 
Amyotrophic lateral sclerosis (ALS) 
Amyotrophic lateral sclerosis (ALS) is a progressive, degenerative disorder 
characterized by the selective loss of motor neurons in the brain and spinal cord 
leading to paralysis, muscle atrophy and eventually, death (Pasinelli & Brown, 
2006). Two missense mutations in the gene encoding the human Vesicle-associated 
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membrane protein (VAMP)-Associated Protein B (hVAPB) causes a range of 
dominantly inherited motor neuron diseases including ALS8 (Nishimura et al., 
2004; Chen et al., 2010). VAP family proteins are characterized by an N-terminal 
major sperm protein (MSP) domain, a coiled-coil (CC) motif and a transmembrane 
(TM)-spanning region. They are implicated in several biological processes, 
including regulation of lipid transport, endoplasmic reticulum (ER) morphology and 
membrane trafficking (Lev et al., 2008). Drosophila Vap-33-1 (DVAP) hereafter, 
regulates synaptic structure, synaptic microtubule (MT) stability and the 
composition of postsynaptic glutamate receptors (Pennetta et al., 2002; Chai et al., 
2008). MSP domains in DVAP are cleaved and secreted into the extracellular space 
where they bind Ephrin receptors (Tsuda et al., 2008). MSPs also bind postsynaptic 
Roundabout and Lar-like receptors to control muscle mitochondria morphology, 
localization and function (Han et al., 2012). Transgenic expression of the disease-
linked alleles (DVAP-P58S and DVAP-T48I) in the larval motor system 
recapitulates major hallmarks of the human disease, including aggregate formation, 
locomotion defects and chaperone upregulation (Chen et al., 2010; Chai et al., 
2008; Ratnaparkhi et al., 2008). Several studies have also implicated the ALS 
mutant allele in abnormal unfolded protein response (UPR) (Chen et al., 2010; 
Kanekura et al., 2006; Langou  et al., 2010; Suzuki et al., 2009; Gkogkas et al., 
2008) and in the disruption of the anterograde axonal transport of mitochondria 
(Mo´rotz et al., 2012). However, it is unclear how these diverse VAP functions are 
achieved and which mechanisms underlie the disease pathogenesis in humans. One 
way to address these questions is to search for DVAP-interacting. We identified 
Sac1 (Suppressor of Actin 1), an evolutionarily conserved phosphoinositide 
phosphatase, as a DVAP-binding protein. Phosphoinositides are low-abundance 
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lipids that localize to the membrane–cytoplasm interface and function by binding 
various effector proteins. The inositol group can be reversibly phosphorylated at the 
3′, 4′ and 5′ positions to generate seven possible phosphoinositide derivatives, each 
with a specific intracellular dynamic distribution (Di Paolo & De Camilli, 2006). 
Interestingly, SAC3 (also known as FIG4), another member of the Sac phosphatase 
family, is mutated in familial and sporadic cases of ALS (Chow et al., 2009). 
Inactivation of SAC3 in mice also results in extensive degeneration and neuronal 
vacuolization in the brain, most relevantly in the motor cortex (Chow et al., 2007). 
We identified Sac1 and DVAP as binding partners and show that DVAP is required 
to maintain normal levels of PtdIns4P. Loss of either Sac1 or DVAP function 
disrupts axonal transport, MT stability, synaptic growth and the localization of a 
number of postsynaptic markers. We also show that the disease causing mutation 
(DVAP-P58S) induces neurodegeneration and displays synaptic phenotypes similar 
to those of either Sac1 or DVAP loss-of-function, including an increase in PtdIns4P 
levels. Importantly, reducing PtdIns4P levels rescues the neurodegeneration 
associated with DVAP-P58S and suppresses the synaptic phenotypes associated 
with DVAP-P58S and DVAP loss-of-function alleles. 
Multiple sclerosis (MS) 
Multiple sclerosis is a chronic idiopathic demyelinating and neurodegenerative 
disease of the central nervous system. As such, both the onset and exacerbation of 
MS are thought to be influenced by multiple factors, including infectious agents, 
genetic composition and environment (Hauser et al, 2006). 
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DEFINITION: 
MS is a chronic disease of the CNS, characterized by discrete areas of demyelination 
and axon injury associated with inflammatory activity as shown in figure 8. A key 
defining feature of MS is that lesions are disseminated in both space and time, i.e., 
they occur at more than one site and develop on more than one occasion. Additional 
information on the pathology of MS is provided below. Clinically, MS symptoms 
emerge Sbetween the ages of 20 and 40 years in approximately 70% of patients 
(Weinshenker et al., 1989; Confavreux et al., 1980) although changes visible on 
MRI are much more common than clinical activity and may well precede the latter 
(O’Riordan et al., 1998; Sailer et al., 1999; Brex et al., 2002). 
 
Figure 8. Demyelination of Myelin Sheath produces multiple sclerosis. 
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SYMPTOMS AND SIGNS: 
Because MS lesions can occur in many different parts of the CNS, they can cause a 
wide variety of symptoms and signs. An exhaustive list of clinical findings seen in 
MS clinics at the Universities of British Columbia and Western Ontario, Canada 
(Paty & Ebers, 1997) together with estimates of the frequencies of each finding at 
onset and at any time. According to this list, initial neurologic symptoms and signs 
seen in 10% or more of patients include fatigue (20%, probably more common than 
this in many populations), optic neuritis (16%), internuclear ophthalmoplegia (17%), 
nystagmus (20%), vertigo (4–14%), gait disturbances (18%), sensory loss (30–50%, 
most commonly in the legs and implicating the posterior columns), increased deep 
tendon reflexes (20%), weakness in the legs (10%), spasticity (10%) and bladder 
disturbance (3– 10%). Symptoms and signs seen in 50% or more of patients at any 
time include cognitive changes (70%), euphoria (10–60%), depression (25–54%), 
fatigue (80%, probably nearer 90% in many populations), optic neuritis (65%), optic 
atrophy (77%), retinal nerve fiber loss (80%), nystagmus (85%), vertigo (5–50%), 
dysarthria (50%), limb ataxia (50%), ataxia of the gait and trunk (50–80%), sensory 
loss (90%, again, most commonly in the legs and implicating the posterior columns), 
increased deep tendon reflexes (90%), weakness in the legs (90%), spasticity (90%), 
extensor or flexor spasms (50%), cramps (50%), amyotrophy (50%), bladder 
disturbance (80%), and sexual disturbance (50% in women, 75% in men). 
COMMON MOTIFS IN NEURO DEGENERATION  
Neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease account 
for a significant and increasing proportion of morbidity and mortality in the 
developed world (Hebert et al., 2001; Hebert et al., 2003). Largely as a result of 
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increased life expectancy and changing population demographics (i.e., the aging of 
baby boomers), neurodegenerative dementias and neurodegenerative movement 
disorders are becoming more common (Brookmeyer et al., 1998; Samii et al., 2004). 
As our population ages, an improved understanding of these diseases will be vital to 
developing more effective therapies and combating the staggering personal, social, 
and economic costs of these diseases (Ernst et al., 1997). Unifying theories of 
pathogenesis in neurodegenerative disease provide an avenue for developing 
therapeutic strategies with broad applicability for disease prevention and an 
opportunity for decreasing morbidity and mortality from these disorders in the 
elderly population (Forman et al., 2004). Converging lines of investigation have 
revealed a potential single common pathogenic mechanism underlying many diverse 
neurodegenerative disorders. 
COMMON NEUROPATHOLOGICAL HALLMARKS: 
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s 
diseases and amyotrophic lateral sclerosis make up a group of pathologies 
characterized by a separated etiology with distinct morphological and 
pathophysiological features. These disorders are defined by a multifactorial nature 
and have common neuropathological hallmarks such as (a) abnormal protein 
dynamics with defective protein degradation and aggregation; (b) oxidative stress 
and free radical formation; (c) impaired bioenergetics and mitochondrial 
dysfunctions; (d) neuro inflammatory processes (Jellinker, 2003; Jellinger, 2010). It 
is difficult to establish the correct sequence of these events, but it has been shown 
that the oxidative damage to the brains of affected individuals is one of the earliest 
pathological markers. Oxidative and nitrosative stresses arise from the imbalance 
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between the increased production of both the reactive oxygen species (ROS) and the 
reactive nitrogen species (RNS) and the cellular antioxidant defense systems (Valko 
et al., 2007). At low levels, ROS function as signaling intermediates for the 
modulation of cellular activities but, at higher concentrations, they contribute to 
neuronal membrane damage. 
ROS is a collective term, which includes not only the oxygen radicals (O2 •−, and 
•OH) but also some non-radical derivatives of oxygen. These include hydrogen 
peroxide (H2O2), hypochlorous acid (HOCl) and ozone (O3) (Bandhopadhyay et al., 
1999).  
Over about 100 disorders like rheumatoid arthritis, hemorrhagic shock, 
cardiovascular disorders, cystic fibrosis, metabolic disorders, neurodegenerative 
diseases, gastrointestinal ulcerogenesis and AIDS have been reported as ROS 
mediated. Some specific examples of ROS mediated diseases include Alzheimer’s 
disease, Parkinson’s disease, Atherosclerosis, Cancer, Down’s syndrome and 
ischemic reperfusion injury in different tissues including heart, liver, brain, kidney 
and gastro intestinal tract. The role played by ROS in stress induced gastric ulcer 
and inflammatory bowel diseases have been well established, as well as their 
involvement in the process of ageing. The role of radicals in various diseases is dealt 
in detail. 
Aging biology 
In the biological process of aging, the following cause–effect relationships are 
demonstrated: formation of intra and intermolecular cross-linkings, as in the case of 
muscle cells aging. Modifications of immunological reactions, usually resulting in 
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decrease of their activities. Telomere shortening with decrease or interruption of cell 
proliferation, which can mean an unbalance between cells lost and reposition rates, 
culmination with organ and system failure and death of the organism. Cell damages 
provoked by free radicals are common during aging; once in this life step cells 
produce less concentrations of antioxidant enzymes like superoxide dismutase 
(SOD), catalase (CAT), etc. Gene activation with inevitable aging-related 
physiological changes (Harman, 1998; Ferrari, 2001). In healthy human 
centenarians, although both plasmatic and red blood cell-SOD were decreased (in 
concentration with the increasing levels since <60 years until 99 years), the 
remarkable increase of plasmatic Vitamins A and E contribute the first indication 
that these vitamins are favorable to longevity (Mecocci et al., 2000). 
Inflammation 
An inflammatory response implicates macrophages and neutrophils, which secrete a 
number of mediators (eicosinoids, oxidants, cytokine and lytic enzymes) responsible 
for initiation, progression and persistence of acute or chronic state of inflammation 
(Lefkowitz et al., 1999). NO along with superoxide (O2 •−) and the products of their 
interaction initiates a wide range of toxic oxidative reactions causing tissue injury 
(Hogg, 1998). Likewise, the neutrophils too produce oxidants and release granular 
constituents comprising of lytic enzymes performing important role in inflammatory 
injury (Yoshikawa & Naito, 2000). Reactive oxygen intermediates (ROI) are 
believed to be mediators of inflammation and responsible for the pathogenesis of 
tissue destruction in rheumatoid arthritis (Valentao et al., 2002). The role of 
ROS/RNS in inflammation is clearly demonstrated by the anti-inflammatory effects 
of the antioxidants. Nitric oxide synthase inhibitors are also effective as anti-
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inflammatory agents in carrageenan-induced rat paw edema method as SOD. These 
may be due to the removal of O2 •− by SOD, so preventing O2 •− dependent 
formation of a factor chemotactic for nutrophils (Miller et al., 1992). 
REACTIVE OXYGEN SPECIES  
There have been several reports on the role of ROS / RNS in neurodegenerative 
diseases. Parkinson’s disease usually appears in the middle to old age often as a 
rhythmic tremor in a foot or hand especially when the limb is at rest. Comparison of 
the brains of Parkinson’s disease with that of the neurologically normal brains shows 
several parameters consistent with increased oxidative stress and defective 
mitochondrial function. Damaged mitochondria may generate more ROS than usual 
and ROS / RNS (includingO2 •−, •OH, ONOO−) can inactivate complex I. Hence it 
is possible that oxidative stress and mitochondrial defects form a vicious cycle 
(Halliwell & Gutteridge, 1999). 
The ROS mainly involved in neurodegeneration are the superoxide anion (O2 −), the 
hydrogen peroxide (H2O2), and the hydroxyl radical (HO•). RNS, such as nitric 
oxide (NO), can react with O2 to produce peroxynitrite (ONOO−), a powerful 
oxidant that may decompose itself to form HO (Spillantini et al., 2011). Cells 
normally employ a number of defense mechanisms against free radical such as 
enzymes (Cu/Zn- and Mn, superoxide dismutase, GSH peroxidase, GSH reductase, 
catalase, and methionine sulfoxide reductase) and low molecular weight antioxidants 
(vitamin E, ascorbate, and GSH) (Markesbery, 1999). Macromolecules such as 
lipids, proteins, and DNA undergo damage and subsequently cell death mainlyby 
apoptosis when the antioxidant defense network is not sufficient (Sayre et al., 2001). 
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Antioxidant defense 
It is evident through the reactions of oxygen, that it is toxic; still only the aerobes 
survive its presence, primarily because they have evolved an inbuilt antioxidant 
defense. Antioxidant defenses comprise: 
• Agents that catalytically remove free radicals and other reactive species like SOD, 
CAT, peroxidase and thio specific antioxidants. 
• Proteins that minimize the availability of peroxidase such as iron ions, copper ions 
and haem. 
• Proteins that protect biomolecules against oxidative damage example heat shock 
proteins. 
• Low molecular mass agents that scavenge ROS and RNS, example GSH, ascorbic 
acid, tocopherol. The antioxidants may be defined as “any substance, when present 
at low concentrations compared with that of an oxidizable substrate that significantly 
delays or prevents oxidations of that substrate”. The term oxidizable substrate 
includes every type of molecule found in vivo. Antioxidant defense include the 
antioxidant enzymes like SOD, CAT, GSH-px, etc, low molecular agents and dietary 
antioxidants (Halliwell & Gutteridge, 1999). 
As stated earlier, Alzheimer’s disease is a process characterized by oxidative 
properties. Therefore, antioxidants, in general, should have positive effects in both 
the prevention and treatment of Alzheimer’s. A study found that antioxidants such as 
vitamin A, vitamin D, lycopene, and beta-carotene were all significantly lower in 
Alzheimer’s disease patients than controls (Foy et al., 1999).The best studied of the 
remaining antioxidants is vitamin C. A study found that plasma vitamin C levels are 
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lower in patients with Alzheimer’s disease and that these levels are associated with 
the degree of cognitive impairment (Riviere et al., 1998).A prospective study of 633 
patients aged 65 years and older found that high-dose supplementation with vitamin 
C decreased the risk of developing Alzheimer’s disease (Morris et al., 1998).None 
of the 23 high-dose vitamin C users in this study developed Alzheimer’s when, 
statistically speaking, 3.3 would have been expected to develop the disease. A case-
control study found that beta carotene levels are lower in Alzheimer’s disease 
patients than in healthy controls (Zaman et al., 1992).A study of 38 Alzheimer’s 
patients and 42 healthy control subjects found that beta carotene levels are lower in 
patients than in healthy individuals (Jimenez-Jimenez et al., 1999).Other 
antioxidants such as selenium, glutamine, taurine, coenzyme Q10, pantethine, and 
magnesium would likely be beneficial to Alzheimer’s patients but have not yet been 
thoroughly studied. Magnesium, for instance, is a particularly good agent to study 
because of its demonstrated to block the absorption of aluminum in the intestines as 
well as across the blood-brain barrier. 
CURRENT SCENARIO 
Neurodegeneration is a process involved in both neuropathological conditions and 
brain ageing. It is known that brain pathology in the form of cerebrovascular and 
neurodegenerative disease is a leading cause of death all over the world, with an 
incidence of about 2/1000 and an 8% total death rate (KolominskyRabas et al., 
1998). Cognitive dysfunction, is a major health problem in the 21st century, and 
many neuropsychiatric disorders and neurodegenerative disorders, such as 
schizophrenia, depression, Alzheimer's Disease (AD) dementia, cerebrovascular 
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impairment, seizure disorders, head injury, Parkinsonism can be severely 
functionally debilitating in nature (Commenges et al., 2000). 
A recent study (Andlin-Sobocki et al., 2005) has evaluated the total cost of brain 
diseases per year, including direct and indirect costs, in 28 countries in Europe at 
about 386 billion Euros for the year 2004. This represented 35% of the total burden 
of diseases affecting about 27% of the 465 million people who are suffering brain 
diseases. If mental disorders are excluded from the calculation the total cost of 
neurological diseases including dementia could be about 146 billion Euros per year 
and the total specific cost of the neurodegenerative diseases could be as much as 72 
billion Euros (Table 1). These diseases are found in about 5% of the total number of 
patients suffering brain diseases. They are characterized by more or less selective 
neuronal degenerations inducing neurological syndromes, and affect both sensory-
motor areas and cognitive functions. 
Table 1.Number of cases and cost per case and per year of neurodegenerative 
diseases in 28 selected European countries (2004)* 
 Number of cases Cost per case/year Total cost/year 
Parkinson’s disease 
 
Dementia 
 
Multiple sclerosis 
1 160 000 
 
4 890 000 
 
380 000 
7 500 Euros 
 
11 000 Euros 
 
24 000 Euros 
8.70 billion Euros 
 
53.80 billion Euros
 
9.12 billion Euros
* from Andlin-Sobocki et al. (2005) 
In industrial countries, PD has a prevalence of approximately 0.3% in the general 
population and affects about 1% of those older than 60 (de Lau & Breteler, 2006). 
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This disease rarely occurs before the age of 50, and men are at higher risk than 
women. In Europe, PD affected 1.2 million people in 2010, resulting in costs per 
patient of EUR 5,626 for direct health care and EUR 4,417 for non-medical care. In 
30 European countries, the total cost of all care for patients with PD in 2010 was 
EUR 13.9 billion (de Lau & Breteler, 2006). 
According to a recent estimation, it is possible that almost 80% of individuals with 
dementia suffer from AD (Jellinger & Attems, 2010). AD is a severe progressive 
neurodegenerative brain disorder that affects approximately 5% of the population 
older than 65 years (Shah et al., 2008). According to the US Centers for Disease 
Control and Prevention (2003), the number of people in the world who are over the 
age of 65 will increase to around 1 billion by 2030. It has also been projected that by 
2050 the number of dementia cases will reach around 14 million in Europe (Mura et 
al., 2010) and 13.2 million in the United States (Hebert et al., 2001). Furthermore, it 
has been estimated that the annual incidence of AD in the United States will increase 
from the 337,000 cases recorded in 1995 to 959,000 cases in 2050 (Hebert et al., 
2001). At the level of individuals, AD decreases the quality of life and shortens life 
expectancy. At the societal level, the long-term care of AD patients in nursing 
homes is an economic challenge in Western countries, as illustrated by a report in 
which Olesen and colleagues (2012) showed that in Europe the annual cost for 
patients with dementia was EUR 105.2 billion in 2010. The mentioned date certainly 
indicate the tremendous impact of AD in terms of the enormous number of patients 
with this disease, the pressure on their relatives, and the negative socioeconomic 
consequences. In short, it can be said that AD is one of the major public health 
problems in the world. 
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CURRENT THERAPEUTIC APPROACHES IN NEURODEGENERATION 
Drugs to improve memory generally work by altering the balance of particular 
chemicals (neurotransmitters) in the brain that are involved in the initial 
Table 2. List of cognition enhancing drugs acting at neurotransmitter level 
SN Category Name Mechanism Comment Reference 
1 Cholinergic 
agents 
Donepezil 
 
 
Galantamine 
 
 
 
Rivastigmine 
Acetylocholinester
ase inhibitor. 
 
Acetylcholinestera
se inhibitor; also 
possible 
cholinergic agonist 
Acetyl 
cholinesterase 
andbutyryl 
cholinesterase 
inhibitor. 
Symptomatic 
treatment of 
AD, 
Vascular 
dementia and 
dementia 
associated 
with PD. 
(Narahash-i 
et al., 2004) 
2 Glutaminergic 
agents 
D-
cycloserine 
 
 
Ampakine 
Memantine 
Partial NMDA 
agonist enhances 
glutamate. 
Signaling 
Significant 
broad 
benefits in 
moderate-to-
severe AD, 
vascular 
dementia and 
combined of 
non-specified 
dementia 
(Lanni et al., 
2008; 
Tullyet al., 
2003; Lynch, 
2004) 
3 Nicotinic 
agonist 
Nicotine Acetylcholine 
agonist and 
Releaser 
Facilitates 
learning/me
mory 
performance 
(Ahijevyc-h 
et al., 2002) 
4 Monoamines 
and agents 
acting on 
them 
Methyl 
-penidate 
 
 
Modafinil 
Effectson 
catecholamine, 
serotonin, 
glutamate,  
gamma amino-
butyric 
acid,orexin, and 
histamine systems 
Improve 
cognition in 
children and 
adults with 
ADHD 
(Turner et 
al., 2004) 
5 Adenosine 
and 
phosphodiest
erase 
Rolipram Selective type-4 
phosphodiesterase 
inhibitor 
Improve LTP (Gong et al., 
2004) 
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learning of a memory or its subsequent reinforcement. Some of them along with 
their mechanism are listed in table 2. Some acts by selective enhancement of 
cerebral blood flow and metabolism, including enhanced glucose uptake, which may 
protect against the effects of hypoxia and ischemia. Reports from literature reveal 
that some medications currently available to patients with memory disorders 
mayalso increase performances in healthy people. Drugs designed for psychiatric 
disorders can also be used to enhance certain mental functions. However, the long-
term effects of these drugs are unknown. Drugs which act as cognition enhancer 
increase synaptic plasticity by, regulating release of neurotransmitter from the pre-
synaptic terminal and increasing sensitivity and specificity of receptors and ion 
channels in the membranes of synapse to neurotransmitter signaling. Some of the 
agents also modulate the process at transcriptional and translational level. 
HERBAL MEDICINES 
In traditional practices of medicine, numerous plants have been used to treat 
cognitive disorders, including neurodegenerative diseases such as Alzheimer’s 
disease (AD) and other memory related disorders. Various studies have been 
undergone to identifying potential new drugs from plant sources, including those for 
memory disorders. There are numerous drugs available in market that have been 
isolated from plants, e.g. alkaloids from plant sources have been investigated for 
their potential in AD therapy, and are now in clinical use. Usually herbal 
preparations are well tolerated but they may have harmful side-effects, including 
interactions with pharmaceuticals (Howes et al., 2003). Herbal medicines, such as, 
Ginkgo Biloba, Bacopamonier (Bramhi) (Das et al., 2002), Shankhpushpi etc. has 
been found to increase memory power. Some of the herbal medicinal plants with 
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potential cognitive enhancement activity are listed in table 3, (Howes & Houghton, 
2003; Kennedy et al., 2003). 
The past decade has also witnessed an intense interest in herbal medicines in which 
phytochemical constituents can have long-term health promoting or medicinal 
qualities. In contrast, many medicinal plants exert specific medicinal actions without 
serving a nutritional role in the human diet and may be used in response to specific 
health problems over short- or long-term intervals. Phytochemicals present in 
vegetables and fruits are believed to reduce the risk of several major diseases 
including cardiovascular diseases, cancers as well as neurodegenerative disorders. 
Therefore people who consume higher vegetables and fruits may be at reduced risk 
for some of diseases caused by neuronal dysfunction (Selvam, 2008; Lobo et al., 
2010). 
Table 3. Some putative cognitive enhancing plants 
Acoruscalamas 
Angelica archangelica 
Asparagus racemosus 
Bacopamonniera 
Biota orientalis 
Boerhaviadiffusa 
Celastruspaniculatus 
Centellaasiatica 
Clitoriaternatea 
Codonopsispilosula 
Convolvulus pluricaulis 
Coptischinensis 
Crocus sativus 
Curcuma longa 
Embeliaribes 
Emblicaofficinalis 
Eugenia caryophyllus 
Evodiarutaecarpa 
Galanthusnivalis 
Ginkgo biloba 
Glycyrrhizaglabra 
Huperziaserrata 
Hydrocotylasiatica 
Lawsoniainermis 
Lycoris radiate 
Magnolia officinalis 
Melissa cordifolia 
Nardostachysjatamansi 
Nicotianatabacum 
Paeoniaemodi 
Panax ginseng 
Piper longum 
Polygonummultiflorum 
Polygala tenuifolia 
Pongamiapinnata 
Rosmarinusofficinalis 
Salvia lavandulifolia 
Salvia miltiorrhiza 
Schizandrachinensis 
Terminaliachebula 
Tinosporacordifolia 
Withaniasomnifera 
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Herbal medicine has long been used to treat neural symptoms. Although the precise 
mechanisms of action of herbal drugs have yet to be determined, some of them have 
been shown to exert anti-inflammatory and/or antioxidant effects in a variety of 
peripheral systems. Now, as increasing evidence indicates that neuroglia-derived 
chronic inflammatory responses play a pathological role in the central nervous 
system, anti-inflammatory herbal medicine and its constituents are being proved to 
be a potent neuroprotector against various brain pathologies. Structural diversity of 
medicinal herbs makes them a valuable source of novel lead compounds against 
therapeutic targets that are newly discovered by genomics, proteomics, and high-
throughput screening. This review will highlight the importance of phytochemicals 
on neuroprotective function and other related disorders, in particular their 
mechanism of action and therapeutic potential (Pueyo & Calvo, 2009). 
Phytochemicals in neuroprotection 
There has been considerable public and scientific interest in the use of 
phytoconstituents for neuroprotection or to prevent neurodegenerative diseases. 
Many phytochemicals have been shown to exert neuroprotective actions in animal 
and cell culture models of neurological disorders. For example, a chalcone (safflor 
yellow B) can protect neurons against ischemic brain injury and piceatannol can 
protect cultured neurons against Aβ-induced death. Epidemiological studies of 
human populations, and experiments in animal models of neurodegenerative 
disorders, have provided evidence that phytochemicals in fruits and vegetables can 
protect the nervous system against disease (Liu, 2003; Joseph et al., 2005). The vast 
majority of studies on health benefits of phytochemicals have focused on the fact 
that many of the active chemicals possess antioxidant activity. Neuroprotective 
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effects of various phytochemicals are associated with reduced levels of oxidative 
stress. For example, resveratrol, quercetin and catechins reduced oxidative stress and 
protected cultured hippocampal neurons against nitric oxide-mediated cell death 
(Larson, 1988). Some of the neuroprotective herbs with their major bioactive 
compound and mode of action were shown in table 4. Hundreds of articles have 
been published reporting neuroprotective effects of compounds in natural products, 
including α-tocopherol, lycopene, resveratrol, ginkgo biloba and ginsenosides (Ikeda 
et al., 2003). 
Flavonoids 
Recently, there has been intense interest in the potential of flavonoids to modulate 
neuronal function and prevent age-related neurodegeneration. Dietary intervention 
studies in several mammalian species, including humans, using flavonoid rich plant 
or food extracts have indicated an ability to improve memory and learning, by 
protecting vulnerable neurons, enhancing existing neuronal function or by 
stimulating neuronal regeneration.  
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Table 4: Nootropic herbs with their active constituents' that help in 
neuroprotection 
 
Individual flavonoids such as the citrus flavanone tangeretin, have been observed to 
maintain nigro-striatal integrity and functionality following lesioning with 6- 
hydroxydopamine, suggesting that it may serve as a potential neuroprotective agent 
against the underlying pathology associated with Parkinson's disease (Youdim et al., 
2004). In order for flavonoids to access the brain, they must first cross the blood 
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brain barrier (BBB), which controls entry of xenobiotics into the brain (Ehrnhoefer 
et al., 2006). Flavanones such as hesperetin, naringenin and their in vivo metabolites, 
along with some dietary anthocyanins, cyanidin-3-rutinoside and pelargonidin-3-
glucoside, have been shown to traverse the BBB in relevant in vitro and in situ 
models (Youdim et al., 2004; Youdim et al., 2002). Anthocyanins can possibly cross 
the monolayer in blood-brain barrier models in vitro. 
Flavonoids and tannins are phenolic compounds that are a major group of 
compounds act as primary antioxidants or free radical scavengers (Polterait, 1997). 
THE ROLE OF PLANT FLAVONOIDS IN NEURODEGENERATION 
There has been a recent explosion of interest by research scientists in the flavonoid 
compounds, with a multitude of medically useful properties having been 
demonstrated in experimental, as well as, clinical studies of flavonoids. For instance, 
flavonoids have been shown to act as powerful free radical scavengers for a 
multitude of free radical species, even the powerful peroxynitrite radical (Jovanovic 
et al., 1998). In addition, several flavonoids have shown powerful metal-chelating 
properties, especially for iron and copper, two of the most potent-free radical 
catalysts (Morel et al., 1998). Of equal importance are several studies that have 
shown that flavonoids interact with cell membranes, improving their fluidity, 
thereby protecting them from lipid peroxidation (Saija et al., 1995; Ratty & Das, 
1988). Along these same lines is the protection of micro vessels in the nervous 
system by specific flavonoids from free radical damage (Kuttan et al., 1981). This 
not only prevents leakage of such vessels, but has been shown to preserve the blood–
brain barrier as well (Robert et al., 1977). There is also evidence that several of the 
flavonoids can inhibit platelet adhesiveness, thereby preventing strokes (Tzeng et al., 
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1991). Finally, some of the flavonoids have the unique ability to inhibit certain 
enzymes, such as the COX-2 enzyme (Kim et al., 1998). 
FLAVONOIDS AS FREE RADICAL SCAVENGERS 
The flavonoid compounds have two properties that make them especially useful as 
antioxidants. First, many are powerful, primary free radical scavengers against a 
wide variety of radicals, including singlet oxygen, superoxide, peroxyl, hydroxyl, 
and the peroxynitrite radicals (Saija et al., 1995). Second, several are known to be 
very effective metal chelators (Duthie et al., 1997). Most flavonoids are present in 
plants as glycosides. In the intestines, this moiety is cleaved off, leaving the 
aglycone form of the flavonoids (Griffiths, 1982). It is the aglycone form that is 
thought to have the highest antioxidant activity in biological systems. There is 
experimental evidence that hydrogen peroxide accumulation occurs during the 
process of catecholamine catabolism, making it especially important in PD (Li et al., 
1995). Recent evidence also indicates that H2O2 plays an important role in the 
toxicity of Alzheimer’s plaques. As we have seen, iron accumulation within neurons 
is characteristic of ageing of the nervous system, but is especially high in the case of 
neurodegeneration. A multitude of phytochemicals have specific properties that 
make them especially useful in combating neurodegeneration, and a list of nutrients 
that stimulate energy generation, primarily through the mitochondrial system. 
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Vernacular Names 
Tamil    : Yanai Nerunjil 
English name    : Land Caltrops 
Hindi name   : Bada Gokshur 
Sanskrit name   : Brihat Gokshur  
Kannada   : Ane Neggilu 
Malayalam   : Ananerinnil  
Oriya    : Gokara  
Marathi   : Gokharu  
Gujarati   : Kadva Gokhru  
Habitat: 
It is distributed in tropical Africa, Ceylon, India, Mexico and Pakistan. It is a 
common herb grows throughout India but it is found commonly along the western 
and corommandal coasts as a weed of waste places. It also occurs in Delhi, 
Rajasthan and Punjab, Tamil Nadu and Gujarat and Deccan peninsula (Sukla & 
Thakur, 1983; Bhakuni et al., 1992). 
Description: 
Large Caltrops is a shrubby, stiff-stemmed herb, native to India, grown for reputed 
medicinal and other uses. It is diffuse annual, much branched, spreading, succulent, 
and glandular, up to 60 cm tall. Roots similar to turmeric in colour. Leaves are 
simple, opposite, ovate or oblong-obovate, 1-4.5 cm long, irregularly and coarsely 
crenate-serrate. Yellow flowers 1.5-2 cm across, stalk 1-2 mm long, increasing up to 
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4 mm in fruit. Sepals 2 mm long; Teeth linear, scaly outside, persistent. Petals fused 
into a broad tube, 1-3 cm long; lobes obtuse. Stamens 0.5-1 cm long; anthers kidney 
shaped. The four angled seed is with 5 extremely sharp spines. It is an important 
famine food - leaves eaten as vegetable. 
Chemical Constituents: 
Fruit : Alkaloids 3.5%–5%, stable oil, aromatic oil, resins, glycosides,  
  carbohydrates, saponins and triterpenoids. 
Stem : Saponins, phytosterols, tannins and carbohydrates. 
Root : Reducing sugars, phenolic compounds, saponins, xanthoproteins,  
  alkaloids, triterpenoids and flavonoids. 
Leaves : Flavonoids, alkaloids, steroids, resins, saponins and proteins. 
Medicinal Uses: 
• Nervine weakness, Pains, Inflammation, Indigestion, Piles, Constipation, Heart 
related problems, Cough, Asthma, Epitasis, Frigidity, Impotence, Renal calculi, 
Dysurea, Infections. 
• Leaves are antibilious. Seeds are demulcent, diuretic, tonic, mucilaginous and 
aphrodisiac. Used in male impotence, gonorrhoea, and incontinence.  
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REVIEW OF LITERATURE 
Pedalium murex has demonstrated antioxidant potential in animal studies. 
Jalaram H et al., (2011) had elucidated IN VITRO ANTIOXIDANT ACTIVITY 
OF AQUEOUS FRUIT EXTRACT OF Pedalium murex. Free radicals are 
involved in more than 80 diseases including Diabetes mellitus, arthritis, 
cancer, ageing, etc. in addition the free radicals are also play role in the 
pathogenesis of liver toxicity, peptic ulcer, diabetic nephropathy etc. In 
treatment of these diseases, antioxidant therapy play key role. Current research 
is now directed towards finding naturally occurring antioxidant of plant origin. 
In Indian system of medicine Pedalium murex is an important medicinal plant 
and it has been used traditionally in various disorders and as a health tonic. To 
understand the mechanisms of pharmacological actions, the in vitro antioxidant 
activity of aqueous extract of fruits of Pedalium murex was investigated for 
DPPH scavenging activity and superoxide scavenging activity. Percentage 
inhibition of free radicals was measured. The antioxidant property may be 
related to the phenolic acids and micronutrients present in the extract. Results 
clearly indicate that Pedalium murex is effective free radical scavenger.  
Srinivas P et al., (2011) had evaluated ANTIOXIDANT ACTIVITY OF Pedalium 
murex FRUITS IN CARBON TETRACHLORIDE INDUCED 
HEPATOPATHY IN RATS. The  decreased  activity  of antioxidant  
enzymes,  such  as  superoxide  dismutase  (SOD), Catalase (CAT), glutathione 
peroxidase  (GPX)  and  glutathione  reductase  (GRD)  in  CCl4  –intoxicated 
rats,  and  its  retrieval towards  near  normalcy  in  CCl4  +  MEC  
administered  rats  revealed  the efficacy of  methanol extract of fruits of 
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Pedalium murex (MEC) in combating oxidative stress due to hepatic damage. 
Elevated level of glutathione transferase(GTS) observed  in  hepatotoxic  rats  
too  showed  signs  of  returning  towards normalcy  in MEC  co-administered  
animals,  thus  corroborating  the  antioxidant  efficacy  of MEC. 
Patel DK et al., (2011) had estimated Pedalium murex L. (PEDALIACEAE) 
FRUITS: A COMPARATIVE ANTIOXIDANT ACTIVITY OF ITS 
DIFFERENT FRACTIONS. Here  the antioxidant activities of Pedalium 
murex were evaluated using six in-vitro assays, namely total antioxidant assay, 
DPPH assay, reducing power, nitric oxide scavenging, hydrogen peroxide 
scavenging and deoxyribose scavenging assays, and total phenol contents were 
also investigated.  
Bhakuni RS et al., (1992) had computed FLAVONOIDS AND OTHER 
CONSTITUENTS FROM Pedalium murex. Two new compounds isolated 
from the fruits of Pedalium murex were characterized as 2′,4′,5′-trihydroxy- 
5,7-dimethoxyflavone and triacontanyl dotriacontanoate by physico-chemical 
methods. Luteolin, rubusic acid, nonacosane, tritriacontane, triacontanoic acid, 
tritriacontanoic acid and sitosterol-β-d-glucoside have also been isolated and 
identified. 
Siva V et al., (2012) had determined EVALUATION OF ANTIPYRETIC 
ACTIVITY OF Pedalium murex AGAINST BREWER’S YEAST-
INDUCED PYREXIA IN RATS. The aqueous and ethanolic extracts of 
Pedalium murex (Pedaliaceae) was investigated for antipyretic activity in rats 
using Brewer’s yeast-induced pyrexia models. Brewer’s yeast (15%) was used 
to induce pyrexia in rats. Both the extract (200 and 400 mg/kg body weight p.o 
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produced a significant (p<0.05) dose dependent inhibition of temperature 
elevation compared with the standard drug Paracetamol (150mg/kg body 
weight). At doses of 200mg/kg b.w, the aqueous extract significantly 
(P<0.001) decreased yeast induced pyrexia in rats. These results indicate that 
leaf extracts of Pedalium murex possesses potent antipyretic effects and thus 
pharmacologically justifying its folkloric use in the management of fever.  
Banji D et al., (2010) had composed SCRUTINIZING THE AQUEOUS 
EXTRACT OF LEAVES OF Pedalium murex FOR THE ANTIULCER 
ACTIVITY IN RATS. Peptic ulcer is manifested largely due to an alteration 
in lifestyle and diet. The antiulcer efficacy of the aqueous extract of leaves of 
Pedalium murex on ethanol induced gastric lesions was investigated in our 
studies. This has been substantiated by ascertaining the content of total acid, 
acid volume, total protein, ulcer index and glutathione. Ulceration was induced 
in 36 hours fasted rats by the administration of 80% ethanol (1 ml/kg) orally. 
The reference standard (famotidine, 3 mg/kg) and aqueous extract of leaves of 
Pedalium murex in doses of 50, 100, 200 mg/kg was given to different groups, 
one hour before the administration of ethanol. Marked gastric mucosal lesions 
were observed with ethanol. A perceptible elevation in ulcer index, total 
acidity, acid volume, total protein and diminution of glutathione was observed. 
Pretreatment with aqueous extract of leaves of Pedalium murex particularly at 
a dose of 200 mg/kg in a single schedule and 100 mg/kg for 15 and 30 days 
treatment annihilated these alterations and elevated the level of glutathione. 
Therefore the aqueous extract of leaves of Pedalium murex could be regarded 
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as a favorable antiulcerogen which could be attributed to its content of 
flavonoids and mucilage.  
Mohana lakshmi S et al., (2012) had presented A REVIEW ON MEDICINAL 
PLANTS FOR NEPHROPROTECTIVE ACTIVITY. Medicinal plants 
may serve as a vital source of potentially useful new compounds for the 
development of effective therapy to combat a variety of kidney problems. 
Many herbs have been proven to be effectual as nephroprotective agents while 
many more are claimed to be nephroprotective but there is lack of any such 
scientific evidence to support such claims. Developing a satisfactory herbal 
therapy to treat severe renal disorders requires systematic investigation of 
properties like acute renal failure, nephritic syndrome and chronic interstitial 
nephritis. Herbal medicines possess curative properties due to the presence of 
their chemical components. The present review is aimed to elucidate the list of 
nephroprotective medicinal plants, which are scientifically proved in treating 
renal disorders.  
Methekar Chandrika et al., (2012) had scrutinized A COMPARATIVE ANTI-
TUSSIVE ACTIVITY OF LAGHU GOKSHURA [Tribulus terrestris Linn.] 
AND BRIHAT GOKSHURA [Pedalium murex Linn.] PANCHANGA IN 
SWISS ALBINO MICE. As  it  is  used  in  the  treatment  of Kasa, in the 
present study a comparative anti-tussive activity of whole plant (Panchanga) 
of Laghuand  Brihat  Gokshura  was  evaluated  against  sulphur  dioxide  
induced  cough  in  mice. The  mice  were  used  as  experimental  animals  and  
were  randomly  divided  in  to  three groups of 6 animals each. The test drugs 
were administered orally at a dose of 780 mg/kg. Recodex, which contains 
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codeine phosphate (2 mg/ml) and chlorpheniramine maleate (0.8 mg/ml), was 
used as standard anti-tussive drug for comparison. The Panchanga of Laghu 
Gokshura and Brihat Gokshura have  shown  moderate  anti-tussive  activity,  
among  them  Brihat  Gokshura  was  found  to  be  better. Hence in non-
availability of root samples of these plants and also to prevent destructive 
harvesting, whole plants can be used in the treatment of Kasa.  
Mukundh N et al., (2008) had assessed ANTI HYPERLIPIDEMIC ACTIVITY 
OF Pedalium murex (LINN.) FRUITS ON HIGH FAT DIET FED RATS. 
The main objective of the study was to investigate about the anti-
hyperlipidemic potential of the ethanolic extract from the fruits of Pedalium 
murex at doses of 200 and 400mg/kg/p.o. in high fat diet fed rats. Biochemical 
parameters like serum total cholesterol (TC), High Density Lipoprotein (HDL), 
Low Density Lipoprotein (LDL), very low density lipoprotein (VLDL) and 
triglycerides (TG) levels were compared with animals concurrently treated 
with reference standards Gemfibrozil and Atorvastatin. The ethanolic extract 
showed a significant decrease in triglycerides (p<0.01), LDL (p<0.001), VLDL 
(p<0.01), cholesterol (p<0.001) and a significant increase in HDL (P<0.05) 
Levels at the tested doses.  
Sharma V et al., (2012) had analyzed A COMPARATIVE STUDY OF 
ETHANOLIC EXTRACTS OF Pedalium murex LINN. FRUITS AND 
SILDENAFIL CITRATE ON SEXUAL BEHAVIORS AND SERUM 
TESTOSTERONE LEVEL IN MALE RATS DURING AND AFTER 
TREATMENT. Present findings provide experimental in-vivo and in-vitro 
evidence that the ethanolic extract of Pedalium murex fruits possesses 
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aphrodisiac property. Study lends growing support for the traditional use of 
Pedalium murex as a sexual stimulating agent and offers a significant potential 
for studying the effect on male sexual response and its dysfunctions. The 
findings justify the concept of Rasayana as rejuvenative tonics and support 
their role in prevention or delay of the aging process.  
DK Patel et al., (2012) had reported APHRODISIAC ACTIVITY OF 
ETHANOLIC EXTRACT OF Pedalium murex LINN FRUIT. The study 
represents an interesting case report for a very good aphrodisiac activity 
observed during an oral glucose tolerance test performed while evaluating the 
antidiabetic potential of Pedalium murex Linn. fruit. Pregnancy was observed in 
the treated groups after 20-25 days of treatment in females which resulted in 
birth of pubs ranging upto ten in some females (more significant in case of 500 
mg/kg p.o.). The observation also showed a significant increase in weights of 
pubs along with a normal behavior pattern. The increased pregnancy rate in the 
drug treated groups may be due to the healthy viable sperm and enhancement 
of sexual desire of the rats.  
Patel K et al., (2012) had enumerated ALDOSE REDUCTASE INHIBITORY 
ACTIVITY OF ALCOHOLIC EXTRACT OF Pedalium murex LINN 
FRUIT. Physico-chemical investigation of ethanolic extract of fruit of the 
Pedalium murex (EPM) was carried out. EPM was screened for aldose reductase 
inhibitory activity using rat lens AR enzyme. HPTLC fingerprinting analysis 
of EPM was performed in chloroform: methanol (8:2) solvent system.  
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Rajashekar V et al., (2012) has studied BIOLOGICAL ACTIVITIES AND 
MEDICINAL PROPERTIES OF GOKHRU (Pedalium murex L.) Bada 
Gokhru (Pedalium murex L.) is perhaps the most useful traditional medicinal 
plant in India. This plant is now considered as a valuable source of unique 
natural products for development of medicines against various diseases and 
also for the development of industrial products. This review gives a bird's eye 
view mainly on the biological activities of some of this compounds isolated, 
pharmacological actions of the extracts, clinical studies and plausible 
medicinal applications of gokhru along with their safety evaluation.  
Muruganantham Sermakkani (2011) had explored EVALUATION OF 
PHYTOCHEMICAL AND ANTIBACTERIAL ACTIVITY OF Pedalium 
murex Linn. ROOT. In  the  present  study,  the  Petroleum  ether,  
Chloroform,  Acetone  and  Methanolic  extract  of  Pedalium murex  L. root 
was  subjected  to preliminary phytochemical compounds and antibacterial 
activity  of certain human pathogenic microorganisms.  The extracts indicated 
the presence of flavonoids, glycosides, steroids, phenols, alkaloids and tannins.  
Maximum antibacterial activity was observed in methanolic extract against 
gram positive bacteria, Streptococcus pyogenes and Enterococcus faecalis than 
the gram negative bacteria.   
Kevalia J et al., (2011) had observed IDENTIFICATION OF FRUITS OF 
TRIBULUS TERRESTRIS LINN. AND Pedalium murex Linn.: A 
PHARMACOGNOSTICAL APPROACH. Gokshura is a well-known 
Ayurvedic drug that is used in many preparations. Botonically it is identified 
as Tribulus terrestris Linn., especially the roots and fruits of the plant. But 
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instead the fruits of another plant Pedalium murex Linn. are commonly used 
and the drug is frequently substituted. Pharmacognostical study has been 
carried out to identify the distinguishing features, both morphological and 
microscopic, of the fruits of Tribulus terrestris Linn. and Pedalium murex 
Linn. This knowledge should help reduce the problem of substitution of the 
genuine drug. 
Sahayaraj K et al., (2008) had pronounced INSECTICIDAL AND 
ANTIFEEDANT EFFECT OF Pedalium murex Linn. ROOT AND ON 
SPODOPTERA LITURA (FAB.) (LEPIDOPTERA: NOCTUIDAE). 
Pedalium murex reduced the food consumption index, growth rate, 
approximate digestability, eficiency of conversion of ingested food, efficiency 
of conversion of digested food of S. litura indicating the antifeedant activity of 
this plant.  Qualitative analysis of Pedalium murex root extract revealed that it 
contains phytochemical such as, steroids, terpenoids, phenolics, saponines, 
tannins and flavanoids. Phenol, 2-(5,6-dimethyl pyrazinyl) methyl  (molecular 
weight 214); O-Terphenyl-13C (molecular weight 230) and 3,3A, 4,9B-
Tetrahydro- 2H-Furo(3,2-C)(1) Benzopyran (molecular weight 206) were 
identified from the ethanol root  extract of Pedalium murex by using GC-MS.  
Pedalium murex impact was more than the neem based biopesticide neem 
gold. Hence this plant can be explored as biopesticidal plant in the near future.  
Patel DK et al., (2011) had outlined Pedalium murex Linn.: AN OVERVIEW OF 
ITS PHYTOPHARMACOLOGICAL ASPECTS. Different parts of the 
plant are used to treat various ailments like, cough, cold and as an antiseptic. 
Phytochemically the plant is popular for the presence of a considerable amount 
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of diosgenin and vanillin which are regarded as an important source and useful 
starting materials for synthesizing steroidal contraceptive drugs and isatin 
alkaloids. Other phytochemicals reported in the plant includes quercetin, 
ursolic acid, caffeic acid, amino acids (glycine, histidine, tyrosine, threonine, 
aspartic acid and glutamic acid) and various classes of fatty acids 
(triacontanoic acid, nonacosane, tritriacontane, tetratriacontanyl and 
heptatriacontan-4-one). Pharmacologically, the plant have been investigated 
for antiulcerogenic, nephroprotective, hypolipidemic, aphrodisiac, antioxidant, 
antimicrobial and insecticidal activities. From all these reports it can be 
concluded that the plant were found to have a better profile with potential 
natural source for the treatment of various range of either acute or chronic 
disease. 
Thamizh Mozhi M et al., (2011) had summarized PHYTOCHEMICAL AND 
PHARMACOGNOSTICAL STUDIES ON Pedalium murex Linn. The 
entire plant of Pedalium Murex Linn. was subjected to various 
Pharmacognostical evaluations like Morphological, Microscopical and Powder 
analysis. Results have revealed clearly that the entire plant is genuine. The 
Phytochemical constituents of Leaves of Pedalium Murex Linn. have been 
worked out. The dry powder of the entire plant was successfully extracted with 
Total  Petroleum  ether  extract,  Alcohol  Extract,  Chloroform  extract,  and  
Aqueous  Extract.  All the extracts were subjected to Preliminary 
Phytochemical screening. It showed the presence of Carbohydrates, 
Glycosides, Alkaloids, Steroids and Flavonoids.  As  per  Materia  medica  
(Krithikar  and  Basu),  studies  are  required  for  the  screening  of various  
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Pharmacological  activities  like  plant  pacifies  vitiated  vata,  pitta,  urinary  
retention,  kidney  stone,  seminal weakness, amenorrhea, inflammation, 
flatulence and fever. 
Shukla YN et al., (1983) had worked on HEPTATRIACONTAN&4&ONE, 
TETRATRIACONTANYL OCTACOSANOATE AND OTHER 
CONSTITUENTS FROM Pedalium murex Linn. Two new compounds 
isolated from the fruits of Pedalium murex are characterized as heptatriacontan-
4-one and tetratriacontanyl octacosanoate by spectral studies. Pentatriacontane, 
sitosterol, hexatriacontanoic acid, hentriacontanoic acid, ursolic acid and 
vanillin have also been isolated and identified. 
Thangadurai Chitra et al., (2013) had revealed LABORATORY AND FIELD 
EFFICACY OF Pedalium murex AND PREDATORY 
COPEPOD, Mesocyclops longisetus ON RURAL MALARIA VECTOR, 
Anopheles culicifacies, To test the potentiality of the leaf extract of Pedalium 
murex and predatory copepod Mesocyclops longisetus (M. longisetus) in 
individual and combination in controlling the rural malarial vector, Anopheles 
culicifacies (An. culicifacies) in laboratory and field studies. Predator survival 
test showed that the methanolic extract of Pedalium murex is non-toxic to the 
predatory copepod, M. longisetus. Experiments were also conducted to evaluate 
the efficacy of methanolic extract of Pedalium murex and M. longisetus in the 
direct breeding sites (paddy fields) of An. culicifacies. Reduction in larval 
density was very high and sustained for a long time in combined treatment 
of Pedalium murex and M. longisetus. 
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3. AIM AND OBJECTIVE 
In this study, we had investigated whether pretreatment and subsequent exposure to an 
acute and chronic unpredictable stress protect the animals from the corresponding 
effects on behavior, cognition, brain antioxidant system and other parameters. 
Stress plays a major role and has a cascading effect on the functioning of the defense 
mechanisms, neuroendocrine, neurotransmitter, behavior, cognition, etc.,  
There are, indeed, a multitude of paradigms assessing various aspects of the 
behavioral performance and cognitive abilities. Till now, some of the paradigms will 
be not used at all in the evaluation of Pedalium murex leaf extract against behavioral 
consequences of adult rats in stress. 
Exposure to stressful events often results in long-lasting changes in the responsivity 
of a variety of systems. For example, repeated exposure to the same stressor 
(homotypic stress) often results in habituation of the hypothalamic–pituitary–adrenal 
(HPA) axis and brain stem catecholaminergic activity. Conversely, exposure to a test 
stressor that is different (heterotypic stress) from that used during the initial repeated 
exposure results in sensitization of the HPA axis and brain stem catecholaminergic 
activity (Sakellaris & Vernikos-Danellis, 1975; Vernikos et al., 1982; Konarska et 
al., 1989; Lachuer et al., 1994). In addition, a single exposure to a stressor has been 
shown to sensitize central pathways involved in drug reward (Pi- azza & Le Moal, 
1998), fear and anxiety (Agid et al., 2000; Goenjian et al.,2000), and neuroendocrine 
responses (van Dijken et al., 1993; Schmidt et al., 1996). 
As human life expectancy has increased, so too has the incidence of stress related 
neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease and 
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Huntington’s disease. Plant extracts have a wide range of medicinal actions, and 
throughout history, they have been used to treat many different types of diseases. In 
the treatment of many diseases, antioxidant therapy plays a key role, so current 
research is now directed towards finding naturally occurring antioxidant of plant 
origin. 
In Indian system of medicine, the plant Pedalium murex is being used to treat many 
illnesses, successfully, for centuries. A number of studies have attributed the 
curative effect of Pedalium murex to its high content of flavonoids. But there is lack 
of studies related with protective effect of Pedalium murex in human and 
experimental animal models too.  
Although Pedalium murex shares many medicinal properties with ‘rasayans’ in 
Ayurvetha, its neuroprotective effect in different experimental neurodegenerative 
models are still debatable. Actually, little is known about the feeding pattern and 
feeding rhythms that underly the hypophagia of the stress treated rats. The general 
behavior, anxiolytic, antidepressant and cognitive, antioxidant enzyme examination 
of the rat whole brain, pattern of food and water intake are used for the first time, to 
assess the protective effect of Pedalium murex against stress induced 
neurodegenerative injury.  We anticipate that the behavioral tests used in the present 
study could contribute to the evaluation of potential drugs effective in the prevention 
of functional deficits induced by neurotoxic agent and may shed an insight into the 
mechanism of action. Hence, a special attention is focused to understand the 
treatment of neurodegenerative diseases by natural phenolic antioxidants from this 
plant. 
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Hence, in order to contribute further to the knowledge of Indian traditional medicine, 
and its sacred and rich history, the objective of the present study is to subject the 
traditionally well-known leaves of Pedalium murex to extraction using suitable 
solvents and the dried extract will be used to evaluate the possible neuroprotective 
effect of Pedalium murex against stress induced rats. 
SPECIFIC OBJECTIVE: 
¾ To elucidate the possible mechanism of action of Pedalium murex by 
employing stress. 
¾ To screen preliminary phytochemicals of ethanol extract of Pedalium murex. 
¾ To study the in vitro antioxidant and radical scavenging and reducing power 
of Pedalium murex. 
¾ To observe behavioral parameters (anxiety, depression and cognition) 
following stress induced neurodegeneration. 
¾ To estimate and study the perturbations in the levels of antioxidant  defense 
systems – SOD, CAT, GSH, LPO and corticosterone in the whole brain of 
the rat.  
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4. PLAN OF WORK 
PHASE I: 
1. Phytochemical Studies: 
¾ Collection and extraction of leaves of Pedalium murex Linn.  
¾ Phytochemical screening of leaves of Pedalium murex Linn. 
2. In vitro antioxidant studies 
a) DPPH radical scavenging activity 
b) Nitric oxide radical scavenging activity 
c) LPO assay  
d) CUPRAC assay 
e) Metal chelating assay 
f) Reducing power 
3.  Bioactive compounds  
a) Total phenol 
b) Total flavonoids 
c) Total tannins 
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PHASE II: 
1) Pharmacological Studies: 
a) Acute oral toxicity study: 
 It will be carried according to the OECD guideline 423. 
      b) Stress induction: 
i) Acute stress: 
 Immobilisation induced stress 
ii) Chronic unpredictable stress: 
 Forced swimming induced stress  
 Immobilisation induced stress 
 Dark phase induced stress 
2) Evaluation of general behavioral alterations in Stress induced rats:  
a) General parameters   
 Body weight 
 Food intake 
 Water intake 
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b) Behavioural studies 
i) Test for anxiety studies 
 Elevated plus maze 
ii) Test for depression 
 Forced swim test 
iii) Test for learning and memory 
 Radial arm maze 
PHASE III: 
Biochemical Analysis 
¾ In vivo antioxidant studies 
 Superoxide dismutase (SOD) 
 Catalase (CAT) 
 Total glutathione (GSH) 
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5. MATERIALS AND METHODS 
Collection of Plant 
The leaves of Pedalium murex was collected from surrounding areas of 
Komarapalayam and vatamalai, Namakkal District, Tamilnadu, India. 
Authentication of Plant 
The Plant was authenticated by Dr. G.V.S. Murthy, scientist F, Botanical survey of 
India, Coimbatore, Tamilnadu (No.BSI/SRC/5/23/2012-13/Tech/1931). 
Extraction Procedure 
The leaves of Pedalium murex were carefully washed with tap water, and dried 
under shade, in room temperature for one week. Then they were ground into powder 
and stored in room temperature. The grind materials were passed though sieve no. 
44 and 72, and the powdered materials of identical size present in-between those two 
sieves were collected and stored in an airtight container for further use. About 
400gm of powdered materials were taken in 1000ml round bottom flask and 
extracted with ethanol for 24 h using cold maceration process with continuous 
stirring. The extract was decanted into pre-weighed glass vials. The solvent present 
in the extract was removed by evaporating at room temperature, to obtain a syrupy 
greenish mass. The extracted residues were weighed and were preserved in a 
vacuum desiccator for subsequent use in the study. 
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PRELIMINARY PHYTOCHEMICAL ANALYSIS  
The ethanolic extract of Pedalium murex (EEPM) was subjected to qualitative tests 
for the identification of various plant constituents (Harborne et al., 2005; 
Krishnaswamy, 2003; Gurudeep et al., 2003; Kasture et al., 2003). 
1) TEST FOR ALKALOIDS 
(a) Dragondorff’s Test: - 1 ml of the extract was added with 1 ml of 
dragondorff’s reagent (potassium bismuth iodide solution). An orange red 
precipitate indicates the presence of alkaloids. 
(b) Mayer’s Test: - 1 ml of the extract was added with 1 ml of Mayer’s 
reagent (potassium mercuric iodide solution). Whitish yellow coloured 
precipitate indicates the presence of alkaloids. 
(c) Hager’s Test: - 1 ml of the extract was added with 3 ml of Hager’s reagent 
(saturated aqueous solution of picric acid), yellow coloured precipitate 
indicates the presence of alkaloids. 
(d) Wagner’s Test: - 1 ml of the extract was added with 2 ml of Wagner’s 
reagent (Iodide in potassium Iodide), formation of reddish brown 
precipitate indicates the presence of alkaloids. 
(e) Tannic acid Test: - 1 ml of the extract was added with 1 ml of 10% tannic 
acid solution, buff coloured indicates the presence of alkaloids. 
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2) TEST FOR SAPONINS 
(a) Foam Test: - The extract was diluted with 20 ml of distilled water and 
shaken in a graduated cylinder for 15 min. lengthwise. A 1 cm layer of 
foam indicates the presence of Saponins. 
(b) Lead acetate Test: - 1 ml of sample solution was treated with 1% lead 
acetate solution, formation of white precipitate indicate the presence of 
saponins. 
(c) Hemolytic Test: - The extract or dry powder was added one drops of blood 
placed on glass slide. If hemolytic zone appears shows the presence of 
saponins. 
3) TEST FOR GLYCOSIDES 
(a) Legal’s Test: - Dissolved the extract in pyridine and added sodium 
nitroprusside solution to make it alkaline. The formation of pink red to red 
colour shows the presence of glycosides.  
(b) Baljet Test: - 1 ml of the test extract was added with 1 ml of sodium 
picrate solution and the yellow to orange colour shows the presence of 
glycosides. 
(c) Keller- killiani Test: - The ethanolic extract 0.5 ml of strong solution of 
lead acetate was added and filtered. The filtrate is shaken with 5 ml of 
chloroform. The chloroform layer is separated in a porcelain dish and 
removes the solvent by gentle evaporation. Dissolve the cool residue in 3 
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ml of glacial acetic acid containing 2 drops of ferric chloride solution. 
Carefully transferred this solution to the surface of 2 ml of concentrated 
sulphuric acid. A reddish brown layer forms at the junction of the two 
liquids and the upper layer slowly becomes bluish green, darkening with 
standing. 
(D) Borntrager’s Test: - Added a few ml of dilute sulphuric acid to 1 ml of 
the extract solution. Boiled, filtered and extracted the filtrate with 
chloroform the chloroform layer was treated with 1 ml of ammonia. The 
formation of red colour of the ammonical layer shows the presence of 
anthraquinone glycosides. 
4) TEST FOR CARBOHYDRATES AND SUGARS 
(a) Molisch’s Test: - 2 ml of the extract was added with 1 ml of α- napthol 
solution was added and also added concentrated sulphuric acid though the 
side of the test tube. Reddish violet colour at the junction of the two liquids 
indicates the presence of carbohydrates. 
(b) Fehling’s Test:- 1 ml of the extract was added with equal quantities of 
Fehling solution A and B were added, upon heating formation of a brick red 
precipitate indicates the presence of reducing sugars. 
(c) Benedict’s test: - 1 ml of extract was added with 5 ml of Benedict’s 
reagent, was added and boiled for 2 min. and cool. Formation of red 
precipitate shows presence of sugars.  
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(d) Tollen’s Test: - 1 ml of extract was added with 2 ml of tollen’s reagent was 
added and boiled. A silver mirror is obtained inside the wall of the tube 
which indicates the presence of aldose sugar. 
(e) Seliwanoff’s Test: - The extract was treated with hydrochloric acid and 
resorcinol and heated. Formation of red colour shows presence of glucose. 
(f) Bromine water Test: - The little quantity of test extract, bromine water was 
added. Bromine water decolorization indicates the presence of aldose sugar. 
 5) TEST FOR TANNINS 
(a) Gelatin Test: - 1 ml of extract was added with 1% gelatin solution 
containing 10% sodium chloride. Formation of white precipitate indicates 
the presence of tannins. 
(b) Ferric chloride Test:-1 ml of extract was added with 1 ml ferric chloride 
solution, formation of dark blue or greenish black product shows the 
presence of tannins. 
(c) Vanillin hydrochloride Test:-1 ml of extract was added with vanillin 
hydrochloride. Formation of purplish red colour indicates the presence of 
tannins. 
(d) Lead acetate Test: - Taken a little quantity of test solution was taken and 
mixed with basic lead acetate solution. Formation of white precipitate 
indicates the presence of tannins. 
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(e) A little quantity of test extract was treated with potassium ferric cyanide and 
ammonia solution. A deep red colour indicates the presence of tannins. 
(f) Potassium dichromate Test:- The sample solution was treated with 1 ml of 
10% Potassium dichromate solution gives yellowish brown precipitate 
indicate the presence of tannins. 
6) TEST FOR FLAVONOIDS 
(a) Shinoda’s Test:- The extract solution, few fragments of magnesium ribbon 
was added and add concentrated HCL drop wise gives cherry red colour 
appears after few min., shows the presence of Flavonoids. 
(b) Alkaline reagent Test: - The extract was treated with sodium hydroxide; 
formation of yellow colour indicates the presence of Flavonoids. 
(c) Little quantity of extract was treated with lead acetate, a yellow colour 
solution formed, disappears on addition of an acid indicates the presence of 
Flavonoids. 
(d) The extract was treated with concentrated sulphuric acid, formation of 
yellow or orange colour indicates the presence of flavonoids.     
7) TEST FOR STEROIDS 
(a) Libermann- Burchard’s Test: - 2 ml of extract was added with chloroform 
solution, 1-2 ml of acetic anhydride and 2 drops of concentrated sulphuric 
acid was added along the sides of the test tube. Appearance of bluish-green 
colour shows the presence of steroids.  
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(b) Salkowsky’s Test:-Dissolve the extract in chloroform solution, 2 ml conc. 
sulphuric acid was added. If chloroform layer appear red colour indicate the 
presence of steroids. 
8) TEST FOR PROTEINS AND AMIN.O ACIDS 
(a) Biuret Test: - 1 ml of the extract was treated with 4% NaOH and few drops 
of CuSO4 solution, Formation of purple violet colour indicate the presence 
of proteins. 
(b) Ninhydrin Test:- 1 ml of the extract was treated with 3 drops of 5% 
Ninhydrin solution in boiling water bath for 10 min.; formation of purplish 
or bluish colour appearance indicate the presence of proteins, peptides or 
amino acid. 
(c) Xanthoproteic Test: - 1 ml of the extract was treated with 1 ml of 
concentrated nitric acid. A white precipitate formed, it was boiled and 
cooled. Then 20% of sodium hydroxide or ammonia is added. Orange colour 
indicates the presence of amino acids. 
(d) Millon’s Test: - 1 ml of the extract was treated with millon’s reagent 
(mercuric nitrate in HNO3) white precipitate turns to brick red indicates the 
presence of proteins.  
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9) TEST FOR TRITERPENOIDS 
(a) Knoller’s Test: - Dissolved 2 or 3 granules of tin metal in 2 ml thionyl 
chloride solution. Then added 1 ml of the extract into the test tube and 
warm, the formation of pink colour indicates the presence of Triterpenoids. 
10) TEST FOR FIXED OILS AND FATS 
(a) Spot Test: - Pressed a small quantity of extract between two filter papers, 
the stain on the filter paper indicates the presence of fixed oils.  
(b) Saponification Test: - Added a few drops of 0.5 N of alcoholic potassium 
hydroxide to small quantity of various extract along with a drop of 
phenolphthalein separately and heat on water bath for 1 to 2 h. The 
formation of soap or partial neutralization of alkali indicates the presence of 
fixed oils and fats. 
11) TEST FOR GUMS AND MUCILAGE 
 10 ml of ethanolic extract was slowly added to 25 ml of absolute alcohol 
with constant stirring, the precipitate was filtered and dried in air. The 
precipitate for its swelling property indicates the presence of carbohydrates. 
IN VITRO ANTIOXIDANT ESTIMATION  
A) FREE RADICAL SCAVENGING ACTIVITY 
♦ DPPH radical scavenging activity: 
The free-radical scavenging activities of these compounds were tested by 
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their ability to bleach the stable radical DPPH. The antioxidant activity using 
the DPPH (1, 1-diphenyl-2- picrylhydrazyl) assay was assessed by the 
method of Blois. The reaction mixture contained 100 µM DPPH in methanol 
and different concentrations (0.5-2.5 µg/ml) of compounds. Absorbance at 
517 nm was determined after 30 min. at room temperature and the 
scavenging activity were calculated as a percentage of the radical reduction. 
Each experiment was performed in triplicate. BHT was used as a reference 
compound. 
♦ Nitric oxide radical scavenging activity: 
The interaction of ethanol extract of Pedalium murex with nitric oxide (NO) 
was assessed by the nitrite detection method. The chemical source of NO 
was sodium nitroprusside (10 mm) in 0.5 m phosphate buffer, pH 7.4, which 
spontaneously produced NO in an aqueous solution. NO interacted with 
oxygen to produce stable products, leading to the production of nitrites. After 
incubation for 60 min. at 37°C, Griess reagent (α-napthyl-ethylenediamine 
0.1% in water and sulphanilic acid 1% in H3PO4 5%) was added. The same 
reaction mixture without the extract of sample but with equivalent amount of 
distilled water served as control. Ascorbic acid was used as positive control. 
♦  LPO assay:  
The mixture (Egg phosphatidylcholine in 5 ml saline) was sonicated to get a 
homogeneous suspension of liposome. Lipid peroxidation was initiated by 
adding 0.05 mM ascorbic acid to a mixture containing liposome (0.1 ml). 
The pink chromogen was extracted with a constant volume of n-butanol and 
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absorbance of the upper organic layer was measured at 532 nm. The 
experiment was performed in triplicate (Sudheerkumar, 2003). 
♦  CUPRAC assay: 
To a test tube, the following solutions were added: 1 mL CuCl2, 1 mL 
neocuproine, and 1mL NH4Ac buffer, and mixed; 0.5 mL of dilute plant 
extract (previously diluted with MeOH at a volume ratio of 1:10) followed 
by 0.6 mL of water were added (total volume = 4.1mL), and mixed. 
Absorbance against a reagent blank was measured at 450 nm after 30 min. 
(the tested plant extracts were checked to reach steady state absorbance 
within this period). The trolox equivalent molar concentration of the plant 
extract sample in final solution may be found by dividing the observed 
absorbance to the molar absorptivity (ε) for trolox (optical cuvette thickness 
= 1 cm). 
♦  Metal chelating assay: 
The reaction mixture containing 1 ml O-Phenanthroline, 2 ml Ferric chloride, 
and 2 ml extract at various concentrations ranging from 2 to 1000 µg/ml in a 
final volume of 5 ml was incubated for 10 min. at ambient temperature. The 
absorbance at 510 nm was recorded. Ascorbic acid was added instead of 
extract and absorbance obtained was taken as equivalent to 100% reduction 
of all ferric ions. Blank was carried out without drug. Experiment was 
performed in triplicate (Sreejayan, 1996; John, 1984; Benzie, 1996). 
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♦  Reducing power: 
The reducing power of extract was determined by the method of Yen and 
Duh. Different concentrations of extracts (0.5-2.5 µg/ml) were mixed with 
2.5 ml of phosphate buffer (200 mM, pH 6.6) and 2.5 ml of 1% potassium 
ferricyanide. The mixtures were incubated at 50°C for 20 min. After 
incubation, 2.5 ml of 10% trichloroacetic acid were added to the mixtures, 
followed by centrifugation for 10 min. The upper layer (5 ml) was mixed 
with 5 ml of distilled water and 1 ml of 0.1% ferric chloride and the 
absorbance of the resultant solution were measured at 700 nm. 
B) BIOACTIVE COMPOUNDS 
♦  Total phenol: 
Total phenolic content was determined by the method described by Singleton 
and Rossi. 1.0 ml of sample was mixed with 1.0 ml of Folin and Ciocalteu's 
phenol reagent. After 3 min. 1.0 ml of saturated Na2CO3 (~35 %) was added 
to the mixture and made up to 10 ml by adding distilled water. The reaction 
was kept in the dark for 90 min. after which its absorbance was read at 725 
nm. A calibration curve was constructed with different concentrations of 
catechol (0.01- 0.1 mM) as standard. The results were expressed as mg of 
catechol equivalents/g of extract. 
♦  Total flavonoids: 
This was assayed as described by Jia et al. 0.5 ml of the sample is added into 
a test tube containing 1.25 ml of distilled water. Then added 0.075 ml of 5 % 
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sodium nitrite solution and allowed to stand for 5 min. Added 0.15 ml of 
10% aluminium chloride, after 6 min. 0.5 ml of 1.0 M sodium hydroxide 
were added and the mixture were diluted with another 0.275 ml of distilled 
water. The absorbance of the mixture at 510 nm was measured immediately. 
The flavonoid content was expressed as mg catechin equivalents /g sample. 
♦  Total tannins: 
The quantitative tannin content in samples was estimated by the method of 
Price and Butler with some modifications. 0.1 g of dry plant sample was 
transferred to 100 ml flask; 50 ml water was added and boiled for 30 min. 
After filtration with cotton filter the solution was further transferred to a 500 
ml flask and water was added to 500 ml mark.  0.5 ml aliquots were finally 
transferred to vials, 1 ml 1% K3Fe(CN)6  and 1 ml 1% FeCl3  were added, 
and was made up to 10 ml with distilled water.  After 5 min. the solutions 
were measured spectrophotometrically at 720 nm. 
ACUTE ORAL TOXICITY STUDIES 
Animals 
Swiss albino mice weighing 20-25 gms were used for the study. The animals were 
housed in propylene cages and were maintained under standard laboratory 
conditions (25° ± 2°c). They were fed with standard diet and water ad libitum. 
Ethical clearance (for handling of animals and the procedures used in study) was 
obtained from the Institutional Animal Ethical Committee before performing the 
study on animals. 
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Acute toxicity test: 
Acute oral toxicity study for ethanolic extract of Pedalium murex leaves was carried 
out as per OECD guideline 423. The test procedure minimizes the number of 
animals required to estimate the acute oral toxicity study. The test allows the 
observation of signs of toxicity and can also be used to identify chemicals that are 
likely to have low toxicity.  
PHARMACOLOGICAL EVALUATION 
Animal study: 
Adult female Sprague Dawley rats were used in the present study. 
Housing and feeding condition: 
All the rats were kept at room temperature (22 ± 30°c). They were housed and 
treated as per the internationally accepted ethical guidelines for the care of 
laboratory animals. Prior to the experiments, rats were fed with standard food, water 
ad libitum and were acclimatized to the standard laboratory conditions of 
temperature (22 ± 30°c) and maintained a 12:12 h light: dark cycle. All the 
experimental procedures were performed on the animals after approval from the 
ethics committee and in accordance with the recommendations for the proper care 
and use of laboratory animals. 
Extract: 
Ethanolic extract of Pedalium murex leaves were suspended in 0.5% Carboxy 
Methyl Cellulose, and was administered once daily to the animals by oral route for 
30 days. 
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Standard drug used: 
Diazepam (2mg/kg, i.p.,) 
Stress Induction: 
Animals remained in their home cages as controls (HCC) or were exposed to stress 
immediately after the extract was given.  After stressor stimulation, rats were returned 
to their home cages. Different animal models for stress have been developed and used 
frequently to evaluate the anti-stress activity of compounds of natural origin.  
Acute models do not reproduce the neuro endocrine models dysfunction whereas 
chronic model might be able to do so, but chronic unpredictable stress prevents the 
emergence of adaptation or resistance to one particular type of stress. Thus we 
preferred two different types of stress to produce different patterns of effects such as,  
♦ Acute stress 
¾ Immobilization induced stress: 
Immobilization has been used extensively as a stressor for the study of stress-
related biological, biochemical and physiological responses in animals 
(Kvetnansky & Mikulai, 1970; Kasuga et al., 1999; Marty et al., 1997). 
Animals were kept immobilized in a semi cylindrical acrylic tube (4.5 cm 
diameter and 12 cm long) with proper holes in it for air to pass (Das et al., 
2000) The rats were kept immobilized for 120 min. (2 h) once to produce acute 
stress (Dronjak & Gavrilovic, 2006). 
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♦ Chronic Unpredictable Stress 
The animals were subjected to 3 varieties of chronic stressors such as forced 
swimming induced stress, immobilization induced stress and dark phase 
induced stress, daily for 10 days from 21st day to 30th day. 
¾ Forced swimming induced stress: 
In order to produce swimming induced stress, rats were made to swim in a 
cylinder (30cm diameter and filled to a height of 20 cm with 15 cm of space 
above the head of the rat) for 30 min. session in a day for ten consecutive days 
(Ferry et al., 1991). 
¾ Immobilization induced stress: 
Animals were kept immobilized in a semi cylindrical acrylic tube (4.5 cm 
diameter and 12 cm long) with proper holes in it for air to pass (Das et al., 
2000) The rats were kept immobilized for 15 min. session upto 10 days to 
produce chronic stress (Dronjak & Gavrilovic, 2006). 
¾ Dark phase induced stress: 
To induce stress, cages of rats were kept in dark room with no light upto 30 
min. per day for 10 days (Marcelo et al., 2007).  
To avoid habituation to stressors, unpredictability was maintained by changing 
the time and sequence of stressors daily during the 10 days of the stress 
paradigm. 
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Experimental Protocol: 
The rats were divided into nine groups of 6 animals each. The treatment period 
comprised of 30 days in four groups, and stress period for chronic unpredictable 
stress (CUS) was 10 days and for acute stress was 2 h. They were grouped under the 
following regimen: 
Group- I, served as control and it received 0.9% normal saline  
Group-II, served as positive control and it received acute stress, Diazepam (2 mg/kg) 
Group- III, served as positive control and it received CUS, Diazepam (2 mg/kg) 
Group- IV, received acute stress only 
Group- V, received CUS only 
Group- VI, pretreated with extract (200 mg/kg) and it received acute stress 
Group- VII, pretreated with extract (400 mg/kg) and it received acute stress 
Group-VIII, pretreated with extract (200 mg/kg) and it received CUS 
Group- IX, pretreated with extract (400 mg/kg) and it received CUS. 
(A) Evaluation of general behavioral alterations in Stress induced rats: 
The animals were subjected to the following behavioral procedures initially and after 
induction of stressors. During the entire period of study the animals were observed for 
any changes in behavior and suitably noted.  
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♦ Measurement of body weight: 
The body weight of the animals was monitored daily by weighing on an 
electrical balance with accuracy to ± 0.1 g. All measurements were made every 
day between 8.30 and 9.15 h, immediately before administration of stress. 
Changes in body weight were calculated by subtracting the weight of the 
animal obtained on last day of stress from that of the animal weight 
immediately before the first stressor.  
♦ Measurement of food intake  
The measurement of food intake was studied by presenting pre-weighed food 
to the animals in all the groups’ immediately following stress and drug 
treatment. The amount of food (Brook Bond, Lipton, India) consumed by the 
animals (food intake in gram /gram weight of rat) was evaluated by weighing 
the remaining amount of food, 24 h after food presentation with accuracy to ± 
0.1 g. Spillage of food pellets was rare, but any obvious spillage was noted and 
those data excluded from the analysis. The food pellets were placed at a height 
accessible to the experimental animals (5 cm from the floor of the cage), so 
they did not need to rear up to reach water and food. Water and food intake 
evaluation started immediately after stress administration. 
♦ Measurements of water intake  
The animals in all groups had free access to water during the entire duration of 
the study. The intake of water was studied by measuring the volume of water 
(water intake in ml / gram body weight of rat) consumed over a 24 h period, 
following induction of stress, in all the groups. Clean water was provided in 
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graduated burettes with drinking spouts allowing direct volumetric 
measurements of intake to the nearest 0.1 ml. The drinking spouts were placed 
at a height accessible to the experimental animals (5 cm from the floor of the 
cage), so that they did not need to rear up to reach water. 
(B) Evaluation of behavioural studies 
♦ Test for anxiety studies 
 Elevated plus maze: 
The elevated plus maze (EPM) was performed on rats as a standard test of 
fear and anxiety, where anxiety-related behavior is measured by the degree 
to which the rodent avoids elevated, unenclosed arms of the maze and 
exhibits defense behaviors such as head dips and scanning posture. The maze 
was elevated 50 cm above ground and consisted of four arms 48 cm in 
length. Two opposing arms were open with no walls, while 48 cm high walls 
enclosed the other two opposing arms. There was a 10 x 10 cm open area at 
the confluence of the four arms. Testing procedures followed the Behavioral 
Neuroscience protocol for elevated plus maze (Current Protocols in 
Neuroscience 2001 John Wiley and Sons: Supplement 10 section 8.3.6 Basic 
Protocol 4). 
One h before animals were put in the maze, they were placed in a darkened 
holding room followed by testing in a dimly lit room. Animals were placed 
individually in the center facing an open arm, and the rodent’s behavior 
recorded by video camera. Tapes were scored by a researcher blind to 
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treatment for 1) first arm preference, 2) entries into closed arms and 3) 
entries into open arms. 
♦ Test for depression 
 Forced swim test: 
A modified forced swim test procedure consisting of an increase in water depth 
was used to enhance sensitivity for detecting putative antidepressant activity of 
drugs (Porsolt et al., 1991). Rats were placed into plastic buckets (19 cm 
diameter, 23 cm deep, filled with 23–25°C water) and videotaped for the entire 
session. As described previously by Porsolt, only the last 4 min. were scored 
for mobility duration. 
♦ Test for learning and memory 
 Radial arm maze: 
The 8-arm radial maze testing was performed to evaluate spatial memory and 
stimulus-response (S–R). Maze arms were 55 x 10 x 10 cm (L x W x H) and 
the center arena was 35 cm in diameter with 20 cm high walls. Feed rewards 
were recessed at the ends of each arm so that the feed was not visible unless 
the animal was adjacent to the edge of the arm. Testing procedures followed 
the Behavioral Neuroscience protocol assessing working vs. reference 
memory (Current Protocols in Neuroscience, 2001 John Wiley and Sons: 
Supplement 4 section 8.5A.1 Basic Alternate Protocol 1). Food bait was 
placed at the ends of four arms after which the animal was placed in the 
center of the maze. The test animal was removed only after 6 min. had 
elapsed. Animals were scored based on number of entries into baited arms 
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and sequence of arms visited. The number of arm entries per min. was also 
recorded. 
(C) Evaluation of biochemical analysis: 
At the end of the behavioural studies, the animal models were anesthetized with mild 
chloroform and sacrificed by cervical dislocation; the whole brain were quickly 
removed, rinsed in ice-cold isotonic saline and packed in an alumin.ium foil for 
further use. 
Test drug and chemicals: 
Corticosterone was purchased from Sigma Aldrich Chemicals, Bangalore. All other 
biochemical and chemicals used for the experiments were of analytical grade 
obtained from SD Fine Chemicals Mumbai, India.  
Preparation of homogenate:  
The brain tissue were  weighed  and  10%  tissue  homogenate  was  prepared  with  
0.025M Tris-Hcl buffer,  pH 7.5. After centrifugation at 10,000 x g for 10 min. the 
resulting supernatant was used for enzyme assays for the estimation of non-
enzymatic and enzymatic antioxidants.  
♦ Estimation of Superoxide Dismutase (SOD):   
Reagents 
Carbonate buffer (100 mM, pH 10.2); Epinephrine (3 mM); 
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Procedure 
The SOD activity in supernatant was measured by the method of Misra and 
Fridovich (1967). The supernatant (500 µl) was added to 0.800ml of carbonate 
buffer (100 mM, pH 10.2) and 100 µl of epinephrine (3 mM). The change in 
absorbance of each sample was then recorded at 480 nm in spectrophotometer 
for 2 min. at an interval of 15 sec. Parallel blank and standard were run for 
determination SOD activity.  
One unit of SOD is defined as the amount of enzyme required to produce 50% 
inhibition of epinephrine auto oxidation. 
Reagents (Standard) (Sample) Blank 
Carbonate 
buffer 
0.900 ml 0.800 ml 1.0 ml 
Supernatant …… 0.1 ml …… 
Epinephrine 0.1 ml 0.1 ml …… 
The reaction mixtures are diluted 1/10 just before taking the readings in 
spectrophotometer. 
Calculation: 
% Inhibition= [X A480nm/min. Uninhibited – X A480nm /min. inhibited X 100] / 
[X A480nm /min. Uninhibited – X A480nm /min. Blank]        
 Units/ml enzyme = [% Inhibition X Vt] / [(50%) X Vs] 
Units/mg protein = [Units/ml enzyme] / [mg protein/ml enzyme]  
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Estimation of Catalase (CAT):   
Reagents 
1. Phosphate buffer solution (50 mM) 
A) Dissolving 6.81 gm of KH2PO4 in 1000 ml distilled water. 
B) Dissolving 6.9 gm of Na2HPO4 in 1000ml distilled water. 
390 ml from solution (A) are mixed with 610 ml from solution (B), the pH is 
adjusted to 7. 
2. Hydrogen peroxide (H2O2) 30 mM 
0.34 ml of 30% H2O2 is diluted with phosphate buffer to 100 ml. 
Procedure 
Catalase activity was measured by the method of Aebi. 0.1 ml of supernatant 
was added to cuvette containing 1.9 ml of 50 mM phosphate buffer (pH 7.0). 
Reaction was started by the addition of 1.0 ml of freshly prepared 30 mM H2O2. 
The rate of decomposition of H2O2 was measured spectrophotometrically from 
changes in absorbance at 240 nm. Activity of catalase was expressed as units/mg 
protein. A unit is defined as the velocity constant per second. 
Reagents Sample Blank 
Phosphate buffer 
solution 
1.9 ml 2..9 ml 
Supernatant 0.1 ml 0.1 ml 
H2O2 1 ml   …… 
 
The reaction occurs immediately after the addition of H2O2. 
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Solutions are mixed well and the first absorbance (A1) is read after 15 seconds 
(t1) and the second absorbance (A2) after 30 seconds (t2).The absorbance is read 
at wave length 240 nm. 
Calculation 
 K= [(Vt/ Vs) x (2.3 x Δt) x (Log A1/ A2) x 60]                                      
 Where, 
    K = Rate constant of the reaction; Δt = (t2 – t1) =15 seconds; A1= absorbance 
after 15 seconds; A2= absorbance after 30 seconds; Vt = total volume (3 ml); 
Vs = volume of the sample (0.1ml); 
♦ Estimation of reduced glutathione (GSH)   
Reduced glutathione (GSH)  was measured by the method of Ellman et al., 
[1959].The PMS of  rat  brain  (720  µl)  and  5%  TCA  were  mixed  to  
precipitate  the  protein  content of  the supernatant. After centrifugation at 
10,000 x g for 5 min. the supernatant was taken.  DTNB (5,5’-dithio-bis(2-
nitrobenzoic  acid  )  Ellman’s  reagent  was  added  to  it  and  the absorbance  
was  measured  at  412  nm.  A standard graph was drawn using different 
concentration of standard GSH solution.GSH contents were calculated in the rat 
brain. 
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6. RESULTS 
Phase I: Phytochemical studies 
5.1.1 Extractive value and percentage yield of EEPM 
The nature of the extract obtained following cold maceration with 90% ethanol and 
percentage yield of leaves of EEPM is shown in Table 5.  
Table 5. Percentage yield and nature of EEPM 
 
5.1.2 Preliminary phytochemical screening of plant extract 
The ethanolic extract of Pedalium murex leaves was analyzed for the presence of 
flavonoids, amino acids, tannins, steroids, glycosides and reducing sugars, etc., 
according to standard methods of Harborne et al., (2005); Kasture et al., (2003) and 
Gurudeep et al., (2003). 
  
Plant / Extract Nature of the extract Extraction Yield  (% w/w)
Ethanol extract of leaves of 
Pedalium murex 
Dark green semisolid 8.34 % 
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 Table 6.  Preliminary phytochemical analysis of Pedalium murex leaf extract 
Phytoconstituents Ethanol Extract 
Reducing sugars + 
Glycosides + 
Alkaloids - 
 Steroids + 
Flavonoids + 
Proteins  - 
Amino Acids + 
Tannins + 
Fixed oils & fats - 
Gum & mucilage - 
Saponins - 
+ Present; - Absent 
5.1.3 In vitro antioxidant studies  
Free radicals are implicated in many disease conditions. Antioxidants may offer 
resistance against the oxidative stress by scavenging free radicals, inhibiting lipid 
peroxidation and by other mechanisms to prevent diseases.  
5.1.3a. Inhibition of DPPH radical 
EEPM had significant scavenging effects on the DPPH radical and the effect was 
found to be enhanced with an increase in the concentration between 10µg/ml and 
50µg/ml of the extract (Figure.9). Compared with that of butylated hydroxyl anisole 
(BHA), the scavenging effect of EEPM was significantly less. The IC50 of EEPM on 
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DPPH radical scavenging assay was found to be 6.87µg/ml. The DPPH radical is 
considered to be a model for a lipophilic radical chain reaction initiated by the lipid 
auto oxidation.  
 
5.1.3b. Inhibition of Nitric oxide radical 
It is known that nitric oxide has an important role in various types of inflammatory 
processes. The concentration of EEPM needed to produce 50% inhibition of nitric 
oxide release was found to be 7.81µg/ml, whereas 15.62µg/ml was needed for 
quercetin, used as a reference compound. The results were shown in Figure.10, 
which illustrates the percentage inhibition of NO generation by EEPM. It is well 
known that nitric oxide has an important role in various types of inflammatory 
processes.  
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Fig. 9 DPPH Assay Of EEPM
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5.1.3c. Lipid peroxidation 
Figure. 11 illustrates the antioxidative activities of various concentrations (µg/ml) of 
EEPM. The IC50 of EEPM was found to between 7.81 and 15.62 µg/ml. The results 
indicate that, EEPM significantly inhibits the linoleic acid peroxidation. The 
antioxidative activity of the leaf extract of EEPM was measured using the 
ammonium thiocyanate method. This method was used to measure the level of 
peroxides, during the initial stages of lipid oxidation. The antioxidant activity of 
EEPM might be due to the reduction of hydrogen peroxide, inactivation of free 
radicals or both. This antioxidant activity of EEPM might be attributed to the 
presence of flavonoids and biflavones.  
 
 
0
20
40
60
80
%
 In
hi
bi
ti
on
concentration (μg/ml)
Fig. 10 Nitric Oxide  Scavenging Assay Of 
EEPM
QUERCETIN EEPM
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5.1.3d. Effect of CUPRAC assay  
Polyphenols are a group of chemicals found in many plants. They possess 
antioxidant properties due to their phenolic –OH group. Polyphenol profiling can be 
done using this CUPRAC methods were various polyphenol groups which differs on 
number and position of –OH groups can be reduced/oxidized by CUPRAC reagent 
which determines the antioxidant capacity of the respective polyphenolic groups. 
Polyphenols, flavonoid containing plant extracts can be measured easily and are 
shown in table7. (Apak et al., 2007; Apak et al., 2006; Lee et al., 2011) 
SAMPLE Copper Reducing Equivalents R
2 
EEPM 675.3109 0.9922 
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Fig. 11 Lipid Peroxidation Assay Of EEPM
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5.1.3e. Effect of EEPM on metal chelating activity 
Transition metals have been proposed as the catalysts for the initial formation of 
radicals. Chelating agents may stabilize transition metals in living systems and 
inhibit the generation of radicals, consequently reducing free radical-induced 
damage. To better estimate the antioxidant potential of the extract, its chelating 
activity was evaluated against Fe2+. The scavenging activity of the sample was found 
to be 9.49 ± 1.543 at the concentration of 30μg/ml. However, the metal chelating 
activity of positive control ethylenediamine tetraacetic acid (EDTA) was found to be 
59.43± 0.7808 (at 30μg/ml) shown in table 8.  
Conc. 
(µg/ml) 
EDTA A 
MEAN MEAN 
30 59.43± 0.7808 9.49± 1.543 
 
5.1.3f. Reductive ability 
It has been demonstrated that the power of certain antioxidant is associated with the 
reducing power of their atoms, which is associated with the presence of reductones.  
During the reducing power assay, the presence of reductants (antioxidants) in the 
tested samples would result in reducing Fe3+/ferricyanide complex to the ferrous 
form (Fe2+). The Fe2+ can therefore be monitored by measuring the formation of 
Perl’s Prussian blue at 700nm. Figure.11 shows the reductive capabilities of EEPM 
and Vitamin C (VIT.C). The reducing power of EEPM and Vitamin C rose with an 
increase in concentration and it was found to be 62.5 and 500µg/ml, respectively.  
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Phenols exhibit significant antioxidant and free radical scavenging ability (Shahidi 
& Naczk, 1995) due to the presence of hydroxyl groups and effective hydrogen 
donating ability. Thus therapeutic properties of PM may possibly be attributed to the 
antioxidant property of phenolic compounds present in EEPM. 
5.1.4b. Estimation of total flavonoids 
Total flavonoid content (expressed as μg quercetin equivalent/ml) were derived from 
a quercetin  standard in the range of 20 -100 µg/ml (R 2= 0.9805).As was observed 
for total polyphenols, total flavonoid contents of the ethanolic extract of Pedalium 
murex (EEPM)was 0.156 μg/ml. 
5.1.4c. Estimation of total tannins 
Quantitative analysis of EEPM for tannic acid content is shown in the table 9. 
SAMPLE TANNIC ACID EQUIVALENT 
Y value at 
100µg/ml R
2 
EEPM 4.3948 0.167 0.9409 
 
5.2 Phase II: Pharmacological studies 
5.2.1 Effect of EEPM on general behavior parameters in acute stress treated 
rats  
Results of behavior studies on acute stress-induced model 
5.2.1. General behavior 
After induction of stress, the animals were observed for general behavior upto 5 
hours. Stress may result in psychological and physiological changes in behavior, 
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attributable to excitotoxicity. The observations made on general behavior for a 
period of 45 minutes following administration of EEPM, diazepam is described 
below:  
Rats treated with stress exhibited a prolonged suppressive behavior in comparison to 
the control rats.  Pretreatment with EEPM 1 hour before stress, resulted in profound 
calmness. Diazepam-treated animals exhibited little or no obviously observable 
behavior effects.   
5.2.2 Effect of Pedalium murex and diazepam on elevated plus maze behavior in 
acute stress-treated rats on day 30. 
Anxiety levels were determined with a plus-maze apparatus and the results are 
shown in figure.13 and table 10. When tested on an elevated plus-maze, a significant 
increase in anxiety levels (time spent in open arms: 20.97±2.9; time spent in closed 
arms: 159.2±9.2) were seen with acute stress-treated rats on Day 1 and a significant 
change in anxiety levels were observed on Day 30 with acute stress rats (time spent 
in open arms: 36.34±7.3; p<0.01; time spent in closed arms: 143.6±13.0), when 
compared to control. 
The rats treated with EEPM in doses employed, produced a significant decrease in 
anxiety levels on Day 1 (time spent in open arms: 55.38±7.625; time spent in closed 
arms: 114.2±11.13) and was found to be even more marked on Day 30 (time spent in 
open arms: 4.172±1.217; time spent in closed arms: 138.5±12.68) with 200 mg/kg 
dose level in comparison to acute stress treated rats. 
Analysis of the results of the first part of the experiment, which examined the effects 
of acute stress on Day 1 in EPM, revealed that the acute stress-treated rats showed 
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significant levels of anxiety as is evident from the time spent in open and closed 
arms.  
Treatment with EEPM in the doses employed exhibited a dose dependent and 
significant decrement in the anxiety parameters studied and was most effective at the 
dose level of 200 mg/kg. 
Table .10 Summary of elevated plus maze in acute stress treated rats 
GROUPS 
TIME SPENT IN ARMS (sec) 
OP ENTRY (DAY30)  CL ENTRY (DAY30) 
Control 6.283±0.7884 173.4±15.19 
Stress 36.34±7.330** 143.6±13.00 ns 
Diazepam 50.67±7.719*** 142.4±8.842 ns 
EEPM 200 8.608±1.117 ns 171.6±12.75 ns 
EEPM 400 29.98±3.889* 150.3±19.65 ns 
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5.2.3 Effect of Pedalium murex and diazepam on forced swim test in acute 
stress-treated rats 
The effects of acute stress, EEPM and diazepam on the duration of immobility of 
rats in the forced swimming test are shown in figure.14 and table 11. Pretreatment 
with EEPM was found to attenuate the period of immobility, significantly (EEPM 
200: 8.608±1.1; EEPM 400: 171.6± 12.7). 
Analysis of the results of the experiment, which examined the effect of acute stress 
(70.27±9.8), following pretreatment for Day 30 by FST, revealed that changes in the 
freezing time displayed by the rats were less apparent when compared with stressed 
group. The duration of immobility was found to be 33.48±8.4 for rats treated with 
diazepam displaying antidepressant activity. 
Table. 11 Summary of forced swim test  in acute stress treated rats 
GROUPS IMMOBILITY TIME ON DAY 30 (in sec) 
Control 55.50±10.30 
Stress 46.00±8.333 ns 
Diazepam 27.15±5.994 ns 
EEPM 200 101.1±12.43** 
EEPM 400 81.24±8.503 ns 
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5.2.9 Effect of Pedalium murex and diazepam on radial arm maze activity in 
acute stress-treated rats 
Analysis of the results of the experiment, which examined the effects of acute stress 
on day 30 on an RAM, showed an increased number of trials, and committed more 
errors in comparison to control rats. EEPM and diazepam treated rats took less trials, 
committed less errors to learn the radial arm-maze in comparison to acute stress-
treated rats. However the number of days to learn the task remained unchanged in 
comparison to vehicle treated groups. Further, the drug treated rats differed in their 
learning pattern in comparison to the control group indicating altered learning.  
The results of 8-arm radial maze testing are shown in figure 15 table 12.A 
significant differences in the errors between the 4 groups (control, acute stress, 
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diazepam and EEPM-treated 200mg/kg and 400mg/kg was apparently observable 
2.67±0.21, 6.17±0.16 and 3.66±0.21 and 5.12± ). The CUS treated group had 
significantly increased errors, time and days (3.17±0.16, 175.58±6.69 and 
06.87±0.33). In this study, treatment with diazepam completely prevented the acute 
stress-induced increase in number of trials, days, and errors largely but not 
completely. 
Table. 12 Summary of radial arm maze studies on acute stress induced rats  
GROUPS NO.OF TRIALS AND ERRORS 
Control 2.492±0.4242 
Stress 4.587±0.4834 ns 
Diazepam 3.199±0.3202 ns 
EEPM 200 3.474±0.7560 ns 
EEPM 400 4.697±0.7667* 
 
 
 
 
 
 
 
 
          Fig.15 Effect of EEPM, diazepam on 8-Arm Radial Maze
 In Acute Stress Treated Rats
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In the present study, EEPM and diazepam completely prevented the errors, time and 
days and a full protection was observed in long-term reference memory, which was 
severely impaired by acute stress. These results indicate that EEPM and perhaps 
diazepam are potential candidates as therapeutic agents for stress-induced brain 
damage 
Results of Pedalium murex and diazepam on behavior in CUS-treated rats 
5.2.4 General behavior 
Induction of CUS for 10 days resulted in sickness, poverty in behavior and, 
invariably all the animals exhibited anxiety & depression after the administration of 
CUS. In comparison to CUS score (0.7±0.18), rats treated with EEPM 200mg/kg 
(1.78±0.32) and EEPM 400mg/kg (1.14± 0.17)scored more in motor activity, in 
similar to diazepam treatment (score 1.72±0.36) and was found to reverse the 
general behavior response on exposure to CUS. They exhibited significantly 
increased hyperactivity and antagonized the effect of these drugs with CUS. 
5.2.5 Feed and water intake 
Administration of CUS markedly increased food intake by about 0.495±0.01 g/g 
body wt. (p<0.01) in comparison to control rats, which consumed 0.3113±0.05 g/g 
body wt.  
The consumption of food with the EEPM treated groups are as follows: 0.335±0.02 
g/g body weight for 200mg/kg and 0.1883±0.013 g/g body weight (p<0.05) for 
400mg/kg respectively. The food intake was found to be markedly reduced with the 
EEPM treated rats. Treatment with diazepam (0.345±0.03 g/g body weight) 
significantly reduced the intake of food (figure 16 and table 13). 
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Induction of CUS notably increased water intake by about 0.7543±0.036 ml/g body 
weight, in comparison to all the groups (0.6357±0.035 ml/g bw. in control, 
0.4243±0.030 ml/g bw. in EEPM 200, 0.3543±0.02487 ml/g bw. in EEPM 400 and 
0.6671±0.04040 ml/g in diazepam), indicating that induction of CUS caused prompt 
but transient increase in water intake, which was antagonized by pretreatment with 
EEPM (figure 17 and table 14). 
Table. 13 Summary of food intake in CUS treated rats. 
GROUPS FOOD INTAKE (in g/g body wt.) 
Control 0.3113±0.054 
Stress 0.495±0.019** 
Diazepam 0.345±0.03344ns 
EEPM 200 0.335±0.02045 ns 
EEPM 400 0.1883±0.01302* 
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Table. 14 Summary of water intake in CUS treated rats. 
GROUPS WATER INTAKE (in ml/g body wt.) 
Control 0.6357±0.03565 
Stress 0.7543±0.03631 ns 
Diazepam 0.6671±0.04040 ns 
EEPM 200 0.4243±0.03046*** 
EEPM 400 0.3543±0.02487*** 
 
 
  
[Type the document title]  Introduction                            
 
Dept. of Pharmacology 186 J.K.K.Nattraja College of Pharmacy 
 
5.2.6 Body weight 
Figure 18 and table 15, show body mass changes of all groups of rats investigated. 
Administration of CUS caused a significant increase in body weight (17.7± 0.67 g; 
p<0.001) in 10 days, from the day of induction of CUS, in comparison to the control 
rats (11.5± 1.5 g). The stress-induced increase of body mass was found to be 
antagonized by treatment with EEPM 200  
Table. 15 Summary of body weight in CUS treated rats. 
GROUPS  BODY WEIGHT (in gram) 
Control 161.5±1.594 
Stress 176.7±0.6703*** 
Diazepam 172.5±1.547*** 
EEPM 200 171.9±0.5132*** 
EEPM 400 171.0±0.6895*** 
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(11.9± 0.51 g; p<0.001), EEPM 400 (17.0± 0.68 g; p<0.001) and diazepam (12.5± 
1.5 g; p<0.001). Pretreatment with EEPM for 30 days protected the rats from 
increase in body mass, in comparison to control rats (11.5± 1.5 g). The body weight 
of rats treated with diazepam was not significantly different from that of controls. 
Treatment with diazepam notably attenuated the increase in body mass induced by 
CUS. 
5.2.7 Effect of Pedalium murex and diazepam on elevated plus maze behavior in 
CUS-treated rats on day 30. 
Tests on anxiety were determined using an elevated plus-maze apparatus and the 
results are shown in figure.19 and table 16. A notable change in anxiety levels were 
observed on day 30 (time spent in open arms: 2.014±0.83; time spent in closed arms: 
136.7±10.42), following 10days of CUS in comparison to control groups (time spent 
in open arms: 1.792±0.44; time spent in closed arms: 136.7±12.28). 
The rats treated with EEPM in the doses employed, produced a marked decrease in 
anxiety levels on day 30 (time spent in open arms: 4.172±1.2; time spent in closed 
arms: 138.5±12.6) with   200 mg/kg dose level in comparison to CUS treated rats. 
The entry into open & closed arm with diazepam treated groups was found to be 
2.61± 0.75 and 154.4± 15.28, respectively.   
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Table. 16 Summary of elevated plus maze in CUS treated rats. 
GROUPS 
TIME SPENT IN ARMS (sec) 
OP ENTRY (DAY30) CL ENTRY (DAY30) 
Control 1.792±0.4439 136.7±12.28 
Stress 2.014±0.8348 ns 136.7±10.42 ns 
Diazepam 2.618±0.7528 ns 154.4±15.28 ns 
EEPM 200 4.172±1.217 ns 138.5±12.68 ns 
EEPM 400 3.621±0.8218 ns 128.0±13.60 ns 
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5.2.8 Effect of Pedalium murex and diazepam on forced swim test in CUS-
treated rats 
The effects of CUS, EEPM and diazepam on the duration of immobility of rats in 
the forced swimming test are shown in figure 20 and table 17. The onset of 
depression in CUS group was evident from increased period of immobility as 
against control (55.50± 10.3 seconds).  
Table. 17 Summary of forced swim test in CUS treated rats. 
GROUPS IMMOBILITY TIME  ON DAY 30  (in sec) 
Control 55.50±10.30 
Stress 46.00±8.333 ns 
Diazepam 27.15±5.994 ns 
EEPM 200 101.1±12.43** 
EEPM 400 81.24±8.503 ns 
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Analysis of the results of the experiment, which examined the effect of CUS 
(46.00±8.33) on Day 30 by FST, revealed that changes in the freezing time 
displayed by the rats were less apparent when compared with EEPM 200 mg/kg 
(immobility period: 101.1±12.43, p<0.01) and EEPM 400 mg/kg (immobility 
period: 81.24± 8.503). The immobility period for diazepam treated group was found 
to be significantly antagonized (57.15± 5.99). 
5.2.9 Effect of Pedalium murex and diazepam on radial arm maze activity in 
CUS-treated rats 
Analysis of the results of the experiment, which examined the effects of CUS on day 
30 on an RAM, showed an increased number of trials, and committed more errors in 
comparison to control rats. EEPM and diazepam treated rats took less trials, 
committed less errors to learn the radial arm-maze in comparison to CUS-treated 
rats. However the number of days to learn the task remained unchanged in 
comparison to vehicle treated groups. Further, the drug treated rats differed in their 
learning pattern in comparison to the control group indicating altered learning.  
The results of 8-arm radial maze testing are shown in Table 18. A significant 
differences in the errors between the 4 groups (control, CUS and EEPM-treated 
200mg/kg and 400mg/kg was apparently observable 2.67±0.21, 6.17±0.16 and 
3.66±0.21 and 5.12± ). The CUS treated group had significantly increased errors, 
time and days (6.17±0.16, 257.62±6.69 and 07.67±0.33). 
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Table 18. Summary of radial arm maze in CUS treated rats. 
GROUPS NO. OF  TRIAL AND ERRORS 
Control 2.609±0.4256 
Stress 6.225±1.132 ** 
Diazepam 3.850±0.3176 ns 
EEPM 200 3.641±0.7557 ns 
EEPM 400 5.065±0.7557 ns 
 
          Fig.21 Effect of EEPM, diazepam on 8-Arm Radial Maze
 In CUS Treated Rats
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In this study, treatment with diazepam completely prevented the CUS induced 
increase in number of trials, days, and errors largely but not completely. 
 In the present study, EEPM and diazepam completely prevented the errors, time and 
days and a full protection was observed in long-term reference memory, which was 
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severely impaired by CUS. These results indicate that EEPM and perhaps diazepam 
are potential candidates as therapeutic agents for stress-induced brain damage. 
5.3 Phase III: Biochemical analysis of brain antioxidants 
5.3.1 Effect of EEPM on rat brain anti oxidant system in acute stress-treated 
rats 
5.3.1a. Effect of EEPM on SOD (U/mg protein) levels in acute stress- treated rat 
brain   
The SOD profile in the rat brain was depicted in Table 17.In comparison to control 
rats (143.7± 74.36), acute stress induction for 2 h resulted in significant reduction of 
SOD level of brain (70.3± 6.306). Pre-treatment with EEPM (200mg/kg: 97.57± 
10.62; 400mg/kg: 147.6± 81.64) for 30 days significantly improve the SOD activity 
in comparison to stress-treated groups in the brain studied. Among all the groups, a 
marked increase in SOD status was observed with EEPM 400mg/kg treatment 
(147.6± 81.64). 
The results suggest a significant dose dependent increase SOD status following 
EEPM pre-treatment for 30 days. Diazepam (115.49± 7.928) significantly attenuated 
the stress effect on SOD status and increased the antioxidant level in all the regions.  
5.3.1b. Effect of EEPM on CAT (U/mg protein) levels in acute stress-treated rat 
brain   
Table 19. showed the alteration of CAT levels in various brain regions studied. In 
comparison to control rats (88.89± 16.66), acute stress induction for 2 h resulted in 
significant reduction of CAT level of brain (15.095± 2.804). Pre-treatment with 
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EEPM (200mg/kg: 50.39± 5.196; 400mg/kg: 79.7± 42.99) for 30 days significantly 
improve the CAT activity in comparison to stress-treated groups in the brain studied.  
Among all the groups, a marked increase in CAT status was observed with control 
groups (88.89± 16.66). The results suggest a significant dose dependent increase 
CAT status following EEPM pre-treatment for 30 days. Diazepam (15.095± 2.804) 
significantly elevated the stress effect on CAT status and increased the antioxidant 
level in all the regions studied.  
5.3.1c. Effect of EEPM on GSH (mg/g protein) levels in acute stress-treated rat 
brain   
The effect of drugs employed on GSH levels are summarized in Table 19. In 
comparison to control rats (4.769± 2.61), acute stress induction for 2 h resulted in 
significant increase of GSH level of brain (86.129± 9.36). Pre-treatment with EEPM 
(200mg/kg: 36.692± 4.99; 400mg/kg: 
Table 19. Effect of EEPM, diazepam on different antioxidant (U/mg protein) 
levels in acute stress-treated rat brain 
GROUPS CAT SOD GSH 
Control 88.72±4.200 143.7±28.18 19.57±1.162 
Stress 4.672±0.3028*** 7.337±1.405*** 16.31±1.089 ns 
Diazepam 20.21±4.773*** 45.49±7.216** 6.370±0.9767* 
EEPM 200 16.07±1.648*** 17.57±2.692*** 4.892±0.7670** 
EEPM 400 107.0±4.111** 147.6±26.56 ns 80.63±6.372*** 
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19.260± 6.19) for 30 days significantly decrease the GSH activity in comparison to 
stress-treated groups in the brain studied.  
Among all the groups, a marked decrease in GSH status was observed with control 
groups (4.769± 2.61). The results suggest a significant dose dependent decrease 
GSH status following EEPM pre-treatment for 30 days. Diazepam (16.998± 5.45) 
significantly diminished the stress effect on GSH status and increased the 
antioxidant level in all the regions studied.  
5.3.2 Effect of EEPM on rat brain anti oxidant system in CUS-treated rats 
5.3.2a. Effect of EEPM on SOD (U/mg protein) levels in CUS- treated rat brain   
The SOD profile in the rat brain was depicted in Table 20. In comparison to control 
rats (143.7± 74.36), CUS induction for 10 days resulted in significant reduction of 
SOD level of brain (16.92± 7.274). Pre-treatment with EEPM (200mg/kg: 107.± 
62.87; 400mg/kg: 153.5± 97.15) for 30 days significantly improve the SOD activity 
in comparison to CUS-treated groups in the brain studied. Among all the groups, a 
marked increase in SOD status was observed with EEPM 400mg/kg treatment 
(147.6± 81.64). 
The results suggest a significant dose dependent increase SOD status following 
EEPM pre-treatment for 30 days. Diazepam (129.84± 62.87) significantly attenuated 
the stress effect on SOD status and increased the antioxidant level in all the regions.  
5.3.2b. Effect of EEPM on CAT (U/mg protein) levels in CUS-treated rat brain   
Table 20. showed the alteration of CAT levels in various brain regions studied. In 
comparison to control rats (88.89± 16.66), CUS induction for 10 days resulted in 
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significant reduction of CAT level of brain (17.85± 3.068). Pre-treatment with 
EEPM (200mg/kg: 57.9± 58.62; 400mg/kg: 81.43± 34.8) for 30 days significantly 
improve the CAT activity in comparison to stress-treated groups in the brain studied.  
Among all the groups, a marked increase in CAT status was observed with control 
groups (88.89± 16.66). The results suggest a significant dose dependent increase 
CAT status following EEPM pre-treatment for 30 days. Diazepam (72.01± 33.97) 
significantly elevated the stress effect on CAT status and increased the antioxidant 
level in all the regions studied.  
5.3.2c. Effect of EEPM on GSH (mg/g protein) levels in CUS-treated rat brain   
The effect of drugs employed on GSH levels are summarized in Table 20. In 
comparison to control rats (56.267± 29.76), CUS induction for 10 days resulted in 
significant increase of GSH level of brain (32.948± 4.84). Pre-treatment with EEPM 
(200mg/kg: 28.001± 8.20; 400mg/kg: 51.477± 29.97) for 30 days significantly 
decrease the GSH activity in comparison to stress-treated groups in the brain 
studied.  
Among all the groups, a marked decrease in GSH status was observed with control 
groups (4.769± 2.61). The results suggest a significant dose dependent decrease 
GSH status following EEPM pre-treatment for 30 days. Diazepam (16.998± 5.45) 
significantly diminished the stress effect on GSH status and increased the 
antioxidant level in all the regions studied.  
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Table 20. Effect of EEPM, diazepam on different antioxidant (U/mg protein) levels 
in CUS-treated rat brain 
GROUPS CAT SOD GSH 
Control 88.59±15.95 143.7±28.18 19.64±0.9595 
Stress 17.42±5.834* 16.92±2.657** 28.27±0.7375*** 
Diazepam 117.6±21.43 ns 69.84±13.81 ns 51.47±0.9506*** 
EEPM 200 154.0±19.04* 247.0±42.17* 57.23±0.8774*** 
EEPM 400 99.77±20.10 ns 153.5±27.90 ns 32.05±1.292*** 
 
• In summary, acute stress produced significant changes in anxiety, depressive and 
cognitive parameters. 
• CUS produced significant increase in anxiety levels in elevated plus-maze and 
depressed the animals in a FST model, and nhanced the impairment in cognitive 
abilities in an 8- arm radial maze. 
•  In addition, CUS caused significantly greater behavioral alterations and changes 
in body weight, food and water intake. 
• The changes in body weight, food and water intake produced by CUS were all 
significantly attenuated by EEPM. 
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DISCUSSION 
The study was undertaken to evaluate the effect of ethanol extract of Pedalium 
murex in acute and chronic stressed rats. Following extraction and preliminary 
identification of phytoconstituents, the extract was studied for in vitro antioxidant 
activities (DPPH, nitric oxide, lipid peroxidation, CUPRAC assay, metal chelation) 
and reducing index. 
The animals were subjected to immobilization induced acute stress and, chronic 
unpredictable stress (CUS) by forced swimming + immobilization + dark phase, for 
10 days. All the animals were pretreated with EEPM for 30 days for acute stress 
model and, 21 days in case of CUS model. 
After subjecting the animals to acute and CUS, changes in food intake, water intake, 
body weight were observed from the time of induction of either acute or chronic 
stress. Thereafter, the animals were subjected to a battery of behavioral studies, viz., 
anxiolytic tests using elevated plus maze, depressive test using forced swim test and, 
impairment of cognition and memory using radial arm maze. Moreover, the 
perturbations in the levels of brain antioxidant system like SOD, CAT were 
measured. In addition, the activities of GSH were also measured. 
The findings of this suggested that the animals exhibited anxiety, depression and, 
impairment of memory and cognition following acute and CUS. EEPM was found to 
attenuate all the changes induces by stress(acute and CUS). EEPM 400 mg/kg was 
found to be most effective in attenuating the effects of acute and CUS and, was 
found to be as potent as diazepam. 
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The acute and CUS paradigm appears to be very robust in inducing an anxiety and 
related mood disorders. The behavioral analyses revealed that the CUS paradigm 
successfully caused severe anxiety in rats, in comparison to acute model of stress. 
The development of anxiety and depression and, impairment of cognition were 
evident as observed from decreased activity in EPM, increased periods of 
immobility in FST and increased errors and trials in an 8 arm radial maze apparatus. 
In the EPM paradigm, an enormous shortening of the entries, and time spent in open 
arms, and prolongation of entries and time spent in closed arms, corresponds to the 
findings in mice (Hliňák & Krejči 1998; Itoh et al., 1990, 1991). Compared to the 
controls, prolonged start and transfer latencies in stress-treated rats indicate that the 
ability to escape rapidly from the open arm into the closed arms is somewhat 
disturbed. In spite of significant recovery with the EEPM treated groups, the scores 
in stress-treated animals exceeded substantially those measured in the controls. It is 
worth mentioning that when placed on the distal end of the open arm, the EEPM and 
stress-treated animals sat motionless. Thereafter, they displayed locomotion 
accompanied with typical arm- and air-sniffing. Thus, both initial immobility and 
freezing of stress-treated animals were replaced by a remarkable exploration. It 
seems that EEPM-treated animals preferred to stay on the open arms. We suggest 
that the preferences of the open arms may relate to reduced anxiety, stress or 
frustration. Animals showing less anxiety spend more time on the open arms of the 
maze whereas animals with higher anxiety level hide in the closed arms (Martinez et 
al., 2002; Pellow et al., 1985). Nevertheless, shortening of transfer latency, seen with 
the EEPM-treated can be interpreted as reflecting a definite ability to remember the 
configuration of the maze. Two different mechanisms, one involved in the 
[Type the document title]  Introduction                            
 
Dept. of Pharmacology 202 J.K.K.Nattraja College of Pharmacy 
 
emotionality and the other triggered by memory formation, may participate in the 
behavioral performance of animals subjected to the EPM task (Rodgers et al., 1997). 
A dissimilar portion of both factors could influence behavioral performance of 
MSG-treated, EEOS-treated and intact animals. Even, it is possible to consider that 
an individual’s reaction towards an anxiogenic stimulus can be changed by cognitive 
processes.  
EEPM treatment also attenuated the stress-induced depression in forced swim test, 
which supports many previous findings. The present data support the view that a 
series of tests and not a single test should be used to characterize animal behavior. 
The testing paradigms used here are reproducible in the evaluation of potential drugs 
effective in the consequent prevention of long-term behavioral functioning induced 
by stress treatment .In this present study, stress produced depression is evident from 
increased freezing time of rats in FST. Treatment with EEPM, in a dose dependent 
manner, attenuated the depressive effects on feeding pattern, water consumption and 
suppression in body weight gain. Rats forced to swim in a restricted area assume an 
immobile posture after initial attempts to escape. In a subsequent immersion, the 
beginning of the immobility is faster and marked. Porsolt et al., (1978) named this 
phenomenon “behavior despair” and attributed the animals’ response to the 
development of a depression process. Treatment with anti-depressive medicines 
reduces the immobility time during the swimming test. The authors presented it as a 
model of animal depression. In the forced swimming test, which evaluates the 
depressive behavior doted by Porsolt, a significant decrease of the immobility time 
was observed after the administration of different doses of EEPM to rats. These 
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results suggest that EEPM induces an anti-depressive activity in the CNS, in a dose-
dependent manner.  
The extract was also found to restore the disturbances in memory and cognitive 
abilities of rats. This was very much evident from the number of trials and errors 
committed by the rats. Memory impairment is a common and usual co-morbidity 
associated with exposure to prolonged stress. Chronic stress has been found to 
induce cognitive dysfunction in psychiatric patients, which leads to the loss of 
synaptic connectivity and perhaps neuronal networks in limbic brain structures 
including the hippocampus and cortex. This further leads to loss of cholinergic 
neurons and results in a state of dementia. Activation of the stress system leads to 
behavioral and hormonal changes that improve the ability of the organism to adjust 
to homeostasis and increase its chances of survival.  
Antidepressant drugs are clinically effective after chronic, but not in acute treatment. 
Similarly, in the present study, chronic EEPM pretreatment attenuated the effects of 
CUS-induced increase in food and water consumption and body weight and, anxiety, 
cognition and depressive behavior of the rats, according to the tests used to analyze 
animal anxiety, cognition and depression. These findings provide further support for 
the similarity between stress-induced immune activation, anxiety and depression. 
The depletion in the levels of SOD and CAT and increased activity of GSH 
following a single and 10 days of acute and CUS, is consistent with previous study 
in our laboratory. These results clearly show that stress can lead to oxidative stress 
leading to neurodegeneration. Treatment with ethanol extract of PM, a herb 
containing among a number of phenolic compounds, flavonoids, tannins, triterpenes, 
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alkaloids, steroids, fixed and volatile oils, significantly attenuated stress-induced 
changes.  
Recent work suggests that different types of stressful events may sometimes produce 
qualitatively different patterns of effects in both behavior and physiology. 
Stress is a common experience of daily life and all organisms have developed 
mechanisms to cope with it. Sustained stress can have numerous pathophysiological 
effects such as activation of neuro–endocrine [limbic-hypothalamic-pituitary adrenal 
system] (Bonfiglio et al., 2001) and hormonal (corticosterone release) functions 
(Fuch and Flugge, 1998). Sustained and persistent stressful conditions can 
precipitate anxiety and affective disorders such as depression, which further lead to 
the excessive production of free radicals and oxidative burden (Maes, 2011). In an 
organism, diverse stressors activate a wide spectrum of interacting hormonal and 
neuronal systems resulting in behavioral (anxiety disorders, decrease in food intake, 
decrease in sexual behavior, and loss of cognitive function) and physiological 
responses [activation of pituitary adrenal axis and release of glucocorticoids into the 
blood stream] (Henry and Stephens, 1977). These stressors are stimulators of arousal 
and lead to autonomic (changes in body temperature and tachycardia) and behavioral 
changes; however, when arousal increases to stress-like levels, it results in 
psychiatric and physical disorders (Hennessy and Levine, 1979).  
Stress responses are variable and there are individual differences both 
physiologically and behaviorally in how an organism perceives a perturbation and in 
the resulting adaptational /maladaptational processes (Weiner. 1992). According to 
previous reports stress induces anxiety-like behavior in both humans and animals 
(Liezmann et al., 2011). Exposure to stress represents an important factor for a 
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number of neuropsychiatric disorders such as depression, post-traumatic stress 
disorder, and other anxiety disorders (Lee et al., 2008).  
Chronic activation of the stress system would be expected to increase visceral 
adiposity, decrease lean body (muscle and bone) mass and suppress osteoblastic 
activity. Antioxidants are known to have great importance in human disease 
pathology because of their possible action against free radicals. Dietary 
macronutrients contribute to the antioxidants defense system. These include β-
carotene, vitamin C, vitamin E. In view of the vital role of oxidative stress in the 
pathogenesis of Alzheimer’s disease (AD), the potential role of these antioxidant 
supplements to prevent AD has gained much interest. 
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7. SUMMARY AND CONCLUSION 
The present study was designed to evaluate the possible protective effect of ethanol 
extract of Pedalium murex (EEPM) leaves treatment against acute and CUS-induced 
neurobehavioral models in SD rats. The neuroprotective effect was assessed using a 
battery of invitro tests, behavioral tests (anxiety, depression and, cognition and 
memory) and biochemical analysis (SOD, CAT, GSH) of the rat brain. 
Phytochemical, total phenolic, tannins and flavonoid content of EEPM and, in vitro 
antioxidant studies on EEPM leaves on various antioxidant systems such as lipid 
peroxidation, DPPH, nitric oxide, CUPRAC assay, metal chelation and reducing 
index were performed. 
Application of acute stress using immobilization for one day and CUS (induced by 
forced swimming + immobilization + dark phase, for 10 days), resulted in elevated 
levels of anxiety, depression and changes in memory and cognitive abilities. 
Pretreatment with EEPM for 30 days prevented the effect of acute and chronic 
unpredictable stress in rats. 
The protective effect of EEPM was evaluated for anxiolytic (elevated plus-maze 
apparatus and depression was evaluated using forced swim test (FST) in both the 
acute and CUS-induced models and moreover, effect of EEPM on learning and  
short-term (spatial) memory was evaluated using a radial arm maze (RAM) test.  
To support the neuroprotective effect of EEPM, the implications of EEPM on 
general behavior, body weight (BW), food intake (FI), water intake (WI) were 
undertaken in acute and CUS-induced models, respectively, as these behavior could 
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be profoundly disturbed in anxiety, depression and may impair memory and 
cognitive abilities. 
Also there may be perturbations in the levels of brain antioxidant enzyme system in 
stressful states. Hence, the effects of EEPM on the levels of glutathione (GSH), 
catalase (CAT), superoxide dismutase (SOD) were studied in the rat brains. 
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